Affymax (AFFY) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 28, 2014	Jun. 30, 2013
Entity Information [Line Items]	'	'	'
Entity Registrant Name	'AFFYMAX INC	'	'
Entity Central Index Key	'0001158223	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Non-accelerated Filer	'	'
Entity Public Float	'	'	$463,771,551
Entity Common Stock, Shares Outstanding	'	37,490,095	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$5,597	$68,265
Short-term investments	0	9,717
Receivable from Takeda	0	18,365
Deferred tax assets	0	363
Prepaid expenses	725	2,731
Other current assets	0	3,069
Total current assets	6,322	102,510
Property and equipment, net	0	2,981
Restricted cash	0	1,135
Long-term investments	0	2,323
Deferred tax assets, net of current	0	6,876
Other assets	1,121	2,392
Total assets	7,443	118,217
Current liabilities	'	'
Accounts payable	101	6,591
Accrued liabilities	581	52,522
Accrued clinical trial expenses	0	2,844
Deposit from Takeda	0	559
Advance from Takeda	8,189	27,715
Notes payable, current	0	8,844
Total current liabilities	8,871	99,075
Long-term income tax liability	0	10,062
Other long-term liabilities	0	799
Total liabilities	8,871	109,936
Commitments and contingencies (Note 9)	'	'
Stockholders' equity	'	'
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock: $0.001 par value, 100,000,000 shares authorized, 37,490,095 and 37,396,717 shares issued and outstanding at December 31, 2013 and 2012, respectively	37	37
Additional paid-in capital	556,672	551,959
Accumulated deficit	-558,137	-543,713
Accumulated other comprehensive income	0	-2
Total stockholders’ equity (deficit)	-1,428	8,281
Total liabilities and stockholders’ equity (deficit)	$7,443	$118,217

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Par value preferred stock	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	37,369,717	35,733,181
Common stock, shares outstanding	37,369,171	35,733,181

STATEMENT_OF_OPERATIONS

STATEMENT OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue:	'	'	'
Collaboration revenue	$1,364	$94,358	$47,703
License and royalty revenue	5	12	17
Total revenue	1,369	94,370	47,720
Operating expenses:	'	'	'
Impairment of inventory and losses on firm purchase commitments	0	44,957	0
Research and development	11,857	51,738	76,308
Selling, general and administrative	27,529	89,714	32,818
Collaboration Cost Reimbursement	-43,451	'	'
Asset Impairment Charges	4,414	'	'
Restructuring Charges	16,066	'	'
Total operating expenses	16,415	186,409	109,126
Loss from operations	-15,046	-92,039	-61,406
Interest income	21	77	169
Interest expense	-1,565	-1,442	-144
Other income (expense), net	8	-34	15
Loss before provision (benefit) for income taxes	-16,582	-93,438	-61,366
Provision (benefit) for income taxes	-2,158	-26	1
Net loss	($14,424)	($93,412)	($61,367)
Net loss per share:	'	'	'
Basic net income (loss) per common share	($0.39)	($2.57)	($1.84)
Weighted-average number of common shares used in computing basic net income (loss) per common share calculation	37,448	36,342	33,288

STATEMENTS_OF_COMPREHENSIVE_LO

STATEMENTS OF COMPREHENSIVE LOSS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Other Comprehensive Income [Abstract]	'	'	'
Net loss	($14,424)	($93,412)	($61,367)
Change in unrealized gains (losses) on investments	2	-20	-13
Other comprehensive loss	2	-20	-13
Comprehensive loss	($14,422)	($93,432)	($61,380)

STATEMENT_OF_STOCKHOLDERS_EQUI

STATEMENT OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid-in Capital	Deferred Stock-Based Compensation	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
In Thousands, except Share data
Balance at Dec. 31, 2010	$72,547	$25	$461,425	$0	($388,934)	$31
Balance (Shares) at Dec. 31, 2010	'	25,451,338	'	'	'	'
Issuance of common stock upon excercise of stock options (shares)	'	95,917	'	'	'	'
Stock Issued During Period, Value, Stock Options Exercised	371	0	371	0	0	0
Issuance of common stock upon vesting of restricted stock units (shares)	'	255,782	'	'	'	'
Issuance of common stock upon vesting of restricted stock units	0	0	0	0	0	0
Proceeds from common stock issued upon public offering, net of issuance costs (shares)	'	9,745,762	'	'	'	'
Proceeds from common stock issued upon public offering, net of issuance costs	53,625	10	53,615	0	0	0
Issuance of common stock related to the employee stock purchase plan (shares)	'	184,382	'	'	'	'
Issuance of common stock related to the employee stock purchase plan	808	1	807	0	0	0
Deferred stock-based compensation	0	0	-5	5	0	0
Amortization of deferred stock-based compensation	-5	0	0	-5	0	0
Employee stock-based compensation	9,773	0	9,773	0	0	0
Nonemployee stock-based compensation	-10	0	-10	0	0	0
Other comprehensive income	-13	'	'	'	'	'
Nonemployee stock-based compensation related to former CEO	268	0	268	0	0	0
Change in unrealized loss on marketable securities	-13	0	0	0	0	-13
Net loss	-61,367	0	0	0	-61,367	0
Balance at Dec. 31, 2011	75,997	36	526,244	0	-450,301	18
Balance (Shares) at Dec. 31, 2011	37,369,717	35,733,181	'	'	'	'
Issuance of common stock upon excercise of stock options (shares)	'	1,129,422	'	'	'	'
Stock Issued During Period, Value, Stock Options Exercised	12,029	1	12,028	0	0	0
Issuance of common stock upon vesting of restricted stock units (shares)	'	222,093	'	'	'	'
Issuance of common stock upon vesting of restricted stock units	0	0	0	0	0	0
Issuance of common stock related to the employee stock purchase plan (shares)	'	224,908	'	'	'	'
Issuance of common stock related to the employee stock purchase plan	1,082	0	1,082	0	0	0
Issuance of warrants related to Loan and Security Agreement	1,394	0	1,394	0	0	0
Issuance of common stock upon net exercise of warrants (shares)	'	60,113	'	'	'	'
Issuance of common stock upon net exercise of warrants	0	0	0	0	0	0
Deferred stock-based compensation	0	0	87	-87	0	0
Amortization of deferred stock-based compensation	87	0	0	87	0	0
Employee stock-based compensation	11,055	0	11,055	0	0	0
Nonemployee stock-based compensation	69	0	69	0	0	0
Other comprehensive income	-20	'	'	'	'	'
Change in unrealized loss on marketable securities	-20	0	0	0	0	-20
Net loss	-93,412	0	0	0	'	0
Balance at Dec. 31, 2012	8,281	37	551,959	0	-543,713	-2
Balance (Shares) at Dec. 31, 2012	35,733,181	37,369,717	'	'	'	'
Issuance of common stock upon excercise of stock options (shares)	'	30,918	'	'	'	'
Stock Issued During Period, Value, Stock Options Exercised	271	0	271	0	0	0
Issuance of common stock upon vesting of restricted stock units (shares)	'	89,460	'	'	'	'
Issuance of common stock upon vesting of restricted stock units	0	0	0	0	0	0
Deferred stock-based compensation	0	0	-3	3	0	0
Amortization of deferred stock-based compensation	-3	0	0	-3	0	0
Employee stock-based compensation	4,445	0	4,445	0	0	0
Other comprehensive income	2	'	'	'	'	'
Change in unrealized loss on marketable securities	2	0	0	0	0	2
Net loss	-14,424	0	0	0	-14,424	0
Balance at Dec. 31, 2013	($1,428)	$37	$556,672	$0	($558,137)	$0
Balance (Shares) at Dec. 31, 2013	37,369,717	37,490,095	'	'	'	'

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities	'	'	'
Net loss	($14,424)	($93,412)	($61,367)
Collaboration Cost Reimbursement	-43,451	'	'
Asset Impairment Charges	5,118	'	'
Restructuring Charge, Noncash	307	'	'
Impairment of inventory and losses on firm purchase commitments	0	44,957	0
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	722	1,987	2,182
Amortization of premium on investments	1	75	55
Stock-based compensation expense	4,442	11,211	10,025
Loss on (gain) on disposal of property and equipment	-704	30	11
Noncash interest expense	811	827	144
Changes in operating assets and liabilities:	'	'	'
Receivable from Takeda	18,365	-9,600	-6,937
Inventory	0	-4,515	'
Prepaid expenses	-441	-5,085	272
Other current assets	3,028	-2,732	-77
Other noncurrent assets	73	-2	-289
Accounts payable	-6,490	5,650	620
Accrued liabilities	-28,335	3,849	2,405
Accrued clinical trial expenses	-2,844	-521	-7,882
Payable to Takeda	0	'	-5,958
Deferred revenue	0	-5,174	-13,322
Deposit from Takeda	-559	-1,438	1,998
Long-term income tax liability	-2,159	-27	18
Advance from Takeda	0	17,767	6,121
Other long-term liabilities	-799	-1,027	15
Net cash used in operating activities	-67,339	-37,180	-71,966
Cash flows from investing activities	'	'	'
Purchases of property and equipment	0	-1,562	-1,265
Payments for of intellectual property license	0	-2,500	0
Purchases of investments	0	-13,233	-35,799
Proceeds from sale of investments	13,175	0	0
Proceeds from maturities of investments and restricted cash	0	45,265	45,024
Proceeds from sale of property and equipment	1,225	25	41
Net cash provided by investing activities	14,400	27,995	8,001
Cash flows from financing activities	'	'	'
Proceeds from issuance of common stock upon exercise of stock options	271	12,029	371
Proceeds from issuance of common stock under employee stock purchase plan	0	1,082	809
Proceeds from common stock issued upon private placement, net of issuance costs	0	0	0
Proceeds from common stock issued upon public offering, net of issuance costs	0	'	53,625
Repayment of notes payable	-10,000	0	0
Proceeds from notes payable	0	10,000	'
Net cash provided by (used in) financing activities	-9,729	23,111	54,805
Net increase (decrease) in cash and cash equivalents	-62,668	13,926	-9,160
Cash and cash equivalents at beginning of the period	68,265	54,339	63,499
Cash and cash equivalents at end of the period	5,597	68,265	54,339
Supplemental disclosures of cash flow information:	'	'	'
Income taxes paid	1	1	1
Interest paid	792	615	0
Supplemental schedule of non-cash financing activities:	'	'	'
Advance from Takeda	0	1,828	0
Change in unrealized gain (loss) on investments	2	-20	-13
Deferred stock-based compensation	3	87	-5
Warrants issued in connection with notes payable	$0	$1,394	$0

The_Company

The Company	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
The Company	'
	The Company
	Affymax, Inc., a Delaware corporation, was incorporated in July 2001. In March 2012, the U.S. Food and Drug Administration, or FDA, approved our first and only product, OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S. We co-commercialized OMONTYS with our collaboration partner, Takeda Pharmaceutical Company Limited, or Takeda during 2012 until February 2013, when we and Takeda announced a nationwide voluntary recall of OMONTYS as a result of safety concerns. Effective April 1, 2013, we entered into an amendment of our collaboration agreement with Takeda pursuant to which Takeda assumed full responsibility for OMONTYS, including responsibility for the ongoing recall and investigation with the FDA, and we granted them an exclusive worldwide license to OMONTYS in consideration for potential milestones and royalties.
	We have experienced significant operating losses since inception. The recall of OMONTYS has severely harmed our business, financial condition, and prospects as a going concern and even with the transition of responsibilities effectuated by the Takeda amendment and the reductions in force, these planned cost reductions may not be sufficient for us to continue as a going concern. The recall has also limited our access to funds. We may be unable to continue our operations or to succeed in the existing and potential future litigation, particularly with the reductions in force and in view of our limited resources and funds. We may explore various strategic alternatives, including a sale of the Company or our assets or a corporate merger. We are considering all possible alternatives, including wind-down of operations or bankruptcy proceedings. As of December 31, 2013, we had an accumulated deficit of $558.1 million.
	Going Concern
	Because we have not made an irrevocable decision to liquidate, the accompanying financial statements have been prepared under the assumption of a going concern basis that contemplates the realization of assets and liabilities in the ordinary course of business. Operating losses have been incurred each year since inception, resulting in an accumulated deficit of $558.1 million as of December 31, 2013. Nearly all of our revenues to date have come from our collaboration with Takeda. As a result of the February 23, 2013 nationwide voluntary recall of OMONTYS and the suspension of all marketing activities, there is significant uncertainty as to whether we will have sufficient existing cash to fund our operations. As of December 31, 2013 we have cash of $5.6 million and current liabilities of $8.9 million. We believe that our cash will be sufficient to fund our operations through the third quarter of 2014, but there is significant uncertainty as to whether our cash will be sufficient to fund our operations past the third quarter of 2014. Given our limited resources, there is no assurance that we will be able to reduce our operating expenses enough to meet our existing and future obligations and conduct ongoing operations. If we do not have sufficient funds to continue operations, we could be required to liquidate our assets, seek bankruptcy protection or other alternatives. Further, given our limited resources, our cash may not be sufficient to fund operations through the third quarter if unforeseen events occur that require additional cash expenditures. These matters raise substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Concentration of Risk
	Our future revenue is based on only one source of product-related revenue, OMONTYS which has bee recalled/discontinued. If Takeda is not successful in identifying the cause of the recall and is unable or unwilling to reintroduce OMONTYS, we have no prospects for other sources of revenue.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	Cash and cash equivalents are stated at cost, which approximates market value. We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
	Restricted Cash
	There is no restricted cash as of December 31, 2103.
	Revenue Recognition
	Collaboration Revenue
	We recognize revenue for contracts entered into prior to 2011 in accordance with the SEC Staff Bulletin No. 101, Revenue Recognition in Financial Statements, as amended by Staff Accounting Bulletin or SAB, No. 104, Revision of Topic 13 and Accounting Standards Codification or ASC, 605-25, Multiple Element Arrangements.  When evaluating multiple element arrangements, we consider whether the components of the arrangement represent separate units of accounting as defined in the authoritative guidance for revenue arrangements with multiple deliverables. Application of this guidance requires subjective determinations and requires management to make judgments about the fair value of the individual elements and whether such elements are separable from the other aspects of the contractual relationship. We continue to follow the guidance of ASC 605-25 to determine whether the components of the Arrangement represent separate units of accounting.  To determine if a delivered item can be treated as a separate unit of accounting, we evaluate (1) if the delivered item(s) has value to Takeda on a standalone basis; (2) there is objective and reliable evidence of fair value of the undelivered item(s) and (3) if a general right of return exists for the delivered item (e.g. contingencies), delivery or performance of the undelivered item(s) is considered probable and is substantially within the control of the company.  We recognize revenue for contracts entered into or materially modified after January 1, 2011, in accordance with Accounting Standards Update, or ASU, No. 2009-13, Multiple Deliverable Revenue Arrangements. This update amends the guidance on accounting for arrangements with multiple deliverables to require that each deliverable be evaluated to determine whether it qualifies as a separate unit of accounting.  This determination is generally based on whether the deliverable has stand-alone value to the customer.  This update also establishes a selling price hierarchy for determining how to allocate arrangement consideration to identified units of accounting.  The selling price used for each unit of accounting will be based on vendor-specific objective evidence, or VSOE, if available, third-party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third-party evidence is available.  We may be required to exercise considerable judgment in determining whether a deliverable is a separate unit of accounting and the estimated selling price of identified units of accounting for new or modified agreements.
	We account for our Arrangement with Takeda under ASC 605-25 and currently, are operating in the commercialization period as defined in the Arrangement.  Before the recall, we were performing commercialization services such as promotions and marketing as well as development work related to OMONTYS post approval.  In return for these services, we receive a 50/50 share of operating profit from the sale and distribution of OMONTYS (as described below), certain milestone payments and contingent payments due under the Arrangement. We also continue to receive reimbursement of costs for commercial and development costs as described in the Arrangement. Prior to approval of OMONTYS, our primary source of revenue consisted of milestone payments and Takeda’s reimbursement of commercialization and development costs.
	In addition to the profit sharing and reimbursement of the costs described above, the Arrangement provided us the potential to earn substantive at risk milestone payments upon achievement of contractual criteria (see Note 3 of Notes to Financial Statements). However, timing and amounts of these milestones are extremely uncertain due to the recall.
	During the commercialization period, our obligations include ongoing regulatory work to obtain and maintain FDA approval and commercialization efforts related to our product launch and promotion and marketing of OMONTYS.
	For each source of collaboration revenue, we apply the following revenue recognition model:
	•	Expense reimbursement revenue. Revenues related to reimbursements by Takeda of third-party development expenses (70/30 split per the Arrangement) and commercialization expenses (shared 50/50 according to the Arrangement) are recognized as revenue in the period the related costs are incurred.  Revenues related to reimbursement of costs of full-time equivalents, or FTEs, engaged in development related activities such as post-marketing studies, are recognized as revenue in the period the related costs are incurred. Such reimbursement is based on contractually negotiated reimbursement rates for each FTE as specified in the Arrangement.  Subsequent to the launch of OMONTYS and recognition of product revenue by Takeda, reimbursement of commercialization expenses and development costs (both FTE and out of pocket costs) associated with post-marketing development activities, is incorporated into the profit equalization revenue as required under the Arrangement in order to effect the 50/50 profit split, as described below.  As part of the Amendment with Takeda, both Parties agreed that they will no longer share expenses related to third-party development (70/30 split) and commercialization (50/50 split) as of April 1, 2013. Except for certain transition services that we performed in April 2013 for full reimbursement of $0.5 million, any expenses incurred by either us or Takeda after April 1, 2013 shall be the responsibility of the respective party and neither us or Takeda has the obligation to share expenses with each other.
	•	Profit equalization revenue/loss. Subsequent to the launch of OMONTYS and prior to the Amendment, as to the recognition of product revenue by Takeda, Takeda allocates the quarterly profit equalization revenue/loss to us in order to effect the 50/50 profit/loss split from the sale of OMONTYS, as called for by the Arrangement.  Profit equalization revenue/loss is calculated as the amount required so that the profit or loss realized by both us and Takeda on the product equates to 50% of the total product profit or loss.  Total product profit or loss on OMONTYS is calculated on a quarterly basis as gross product sales recorded by Takeda less the following deductions also recorded by Takeda: rebates and discounts, cost of goods, and other gross-to-net adjustments incurred by Takeda; royalty expenses incurred by us, commercialization expenses (FTE related and out of pocket costs) incurred by both Takeda and us, and certain development costs associated with post-marketing development activities (FTE related and out of pocket costs) incurred by both Takeda and us.  Profit equalization revenue is recognized as revenue in the period product revenue is recognized by Takeda.  As a result of the voluntary recall of OMONTYS in February 2013, all marketing activities were suspended. As part of the Amendment with Takeda, the profit equalization revenue for the three months ended March 31, 2013 will be the final profit equalization payment under the Arrangement. Upon signing the Amendment with Takeda, the economics of the collaboration changed from a profit sharing arrangement to a milestone and royalty-based compensation structure to us, effective April 1, 2013.
	•	Milestone revenue. We account for milestones under ASU No. 2010-17, Milestone Method of Revenue Recognition. Under the milestone method, contingent consideration received from the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved, which we believe is more consistent with the substance of our performance under the collaboration. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the entity. A milestone is substantive if the consideration earned from the achievement of the milestone is consistent with our performance required to achieve the milestone or the increase in value to the collaboration resulting from our performance, relates solely to our past performance, and is reasonable relative to all of the other deliverables and payments within the collaboration. Although we are eligible to receive future milestones from Takeda, timing and amounts of future milestone payments, if any are extremely uncertain due to the recall.
	Below is a summary of the components of our collaboration revenue for the years ended December 31, 2013, 2012, and 2011 (in thousands):
		Year ended December 31,
		2013				2012			2011
	Profit equalization revenue	$	5			$	26,544		$	—
	Milestone payments	—				60,250			10,000
	Revenue previously deferred related to API	—				936			—
	Revenue recognized under CAPM	—				—			26,606
	Net expense reimbursement after CAPM	1,364				6,628			11,097
	Total collaboration revenue	$	1,369			$	94,358		$	47,703
	License and Royalty Revenue
	Royalties are recognized as earned in accordance with contract terms, when third party results are reported and collectability is reasonably assured.  Royalties received under agreements that were acquired by us in the 2001 spin out from GlaxoSmithKline or Glaxo are recorded net of the 50% that we are required to remit to Glaxo.
	If Takeda decides to reintroduce OMONTYS, which is highly uncertain, we are eligible to receive potential milestones and royalties. The royalties are tiered in the range of 13% to 17% with respect to net sales in the U.S. and in the range of 13% to 24% depending on the level of net sales by Takeda worldwide outside of the U.S.
	Fair Value of Financial Instruments
	For financial instruments consisting of cash and cash equivalents, receivable from Takeda, advance from Takeda, accounts payable, deposit from Takeda and accrued liabilities included in our financial statements, the carrying amounts are reasonable estimates of fair value due to their short maturities. Estimated fair values for short-term and long-term investments are based on quoted market prices for the same or similar instruments. Based on borrowing rates currently available to us for loans with similar terms, the carrying value of lease obligations approximates fair value.
	Inventory
	We value our inventories at the lower of cost or net realizable value which is contractually determined in our collaboration with Takeda to be our cost plus a markup.  We determine the cost of inventory using the specific identification method.  We record API as inventory when the title transfers to us from the CMO, until the point of acceptance by Takeda. We initiate orders for API with our CMOs based on forecasts from Takeda. To date all orders have generally commenced once there was a contractual commitment for the API from Takeda.
	We analyze our inventory levels quarterly and write down inventory that has become obsolete or has a cost basis in excess of its expected net realizable value, as well as any inventory quantities in excess of expected requirements.  Any expired inventory is disposed of and the related costs are recognized as expense. The voluntary recall of OMONTYS in February 2013 impacted the recoverability of our inventories based on assumptions about expected demand and net realizable value. In the December 31, 2012 balance sheet, given the significant uncertainty of demand following the recall, we had written down our API inventory and prepayments made to our CMOs to the net realizable value of zero. We also established an accrual for estimated losses on firm inventory purchase commitments by applying the same lower of cost or market approach that is used to value inventory. As of March 31, 2013 this accrued commitment was $32.9 million. However, in the second quarter of 2013, we were able to settle these obligations for $11.0 million resulting in a favorable adjustment to our operating results of $21.9 million in the quarter ended June 30, 2013. As of December 31, 2013, there was no remaining manufacturing obligations or accrued balance.
	We expense costs relating to the production of API as research and development or R&D expense in the period incurred until we receive FDA approval for a new product or product configuration and began to capitalize the subsequent inventory costs relating to that product or product configuration. Prior to approval of OMONTYS for commercial sale in March 2012 by the FDA, we had expensed all costs associated with the production of API as R&D expense. Subsequent to receiving FDA approval of OMONTYS, we commenced capitalization of third party costs which are incurred to manufacture the API used in the production of OMONTYS.
	Property and Equipment
	Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are calculated using the straight-line method over the estimated useful lives of the assets, generally three to five years. Assets under capital lease and leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the related lease. Maintenance and repairs are charged to operations as incurred. All equipment was determined to be held for sale in May 2013 and accordingly no further depreciation was recorded after that determination. Equipment categorized as held for sale on the balance sheet during the year and subsequently sold had a net book value of $0.5 million. All equipment other than computers retained for data storage was sold as of June 30, 2013 and the carrying value of equipment was reduced to zero upon completion of the sale.
	Valuation of Long-Lived Assets, Prepaids and Other Assets
	We assess the impairment of long-lived assets when events or changes in circumstances indicate that the carrying value of the assets or the asset grouping may not be recoverable. Factors that we consider in deciding when to perform an impairment review include significant negative industry or economic trends, and significant changes or planned changes in our use of the assets. We measure the recoverability of assets that will continue to be used in our operations by comparing the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping's carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired. The impairment is measured by comparing the difference between the asset grouping's carrying value and its fair value. Fair value is the price that would be received from selling an asset in an orderly transaction between market participants at the measurement date. Long-lived assets such as intangible assets and property, plant and equipment are considered non-financial assets, and are recorded at fair value only when an impairment charge is recognized. The recall of OMONTYS was considered to be an impairment indicator for certain assets. We evaluated the recoverability of our assets and determined that certain assets were impaired. We recorded impairment charges for the year ended December 31, 2013 of $4.4 million. These charges are reflected in the statement of operations under the caption "Impairment (gain on disposal) of prepaid expenses, fixed assets, and intangible assets.
	Net Loss Per Common Share
	Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period.  Stock options, warrants, unvested restricted stock units or RSUs, and common stock issuable pursuant to the 2006 Employee Stock Purchase Plan were not included in the diluted net loss per common share calculation for the periods presented because the inclusion of such shares would have had an antidilutive effect.
	The computations for basic and diluted net loss per share are as follows (in thousands):
		Year ended December 31,
		2013				2012			2011
	Numerator:
	Net loss	$	(14,424	)		$	(93,412	)	$	(61,367	)
	Denominator:
	Weighted-average number of common shares used in computing basic and diluted net loss per common share	37,448				36,342			33,288
	Basic and diluted net loss per common share	$	(0.39	)		$	(2.57	)	$	(1.84	)
	The following shares were excluded from the computation of diluted net loss per common share for the periods presented because including them would have an antidilutive effect (in thousands):
		Year ended December 31,
		2013			2012			2011
	Options to purchase common stock	1,840			4,858			4,262
	Common stock issuable pursuant to the 2006 Employee Stock Purchase Plan	—			40			41
	Restricted stock units	—			297			362
	Warrant to purchase common stock	424			424			426
	Stock-Based Compensation
	We account for equity instruments issued to employees and directors under the authoritative guidance for share-based payments.
	The equity instruments we most typically grant are stock options and RSUs. Stock options are valued using the Black-Scholes valuation model while the fair value of RSUs is equivalent to the market value of the equivalent number of shares of common stock on the date of grant. The measurement of stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest or do not vest as a result of employee terminations prior to vesting.
	We have issued stock options to non-employees. We account for equity instruments issued to non-employees in accordance with the authoritative guidance for equity-based payments to non-employees, using a fair value approach.
	During the quarter ended June 30, 2013, we terminated the Employee Stock Purchase Plan and the Restricted Stock Award Plan.

Development_and_Commercializat

Development and Commercialization Agreements with Takeda	12 Months Ended
	Dec. 31, 2013
Development and Commercialization Agreements [Abstract]	'
Development and Commercialization Agreements with Takeda	'
	Development and Commercialization Agreements with Takeda
	We entered into two separate collaboration agreements with Takeda in February 2006 and June 2006 related to the co-development and co-commercialization of OMONTYS, which have been combined for accounting purposes due to their proximity of negotiation. We previously amended these arrangements in November 2011 concurrent with the settlement and license agreement, or Settlement and License Agreement, with Janssen (see further discussion below and Note 4 of Notes to Financial Statements).
	On February 23, 2013, we and Takeda announced a nationwide voluntary recall of OMONTYS as a result of post-marketing reports regarding safety concerns, including anaphylaxis. As a result of the voluntary recall of OMONTYS, all marketing activities were suspended. Effective April 1, 2013, we and Takeda entered into the Amendment to the February 2006 and June 2006 agreements to amend and restate the ongoing respective roles and responsibilities and related commitments and financial terms between the Parties, including the termination of the Collaboration and License Agreement dated as of February 13, 2006, under which we had granted Takeda a certain right and license for the development and commercialization in Japan of OMONTYS, as amended by the First Amendment, dated April 1, 2007, the Second Amendment, dated January 1, 2008 and the Third Amendment, dated November 7, 2011, as well as the related manufacturing supply, safety, quality and co-promotion agreements between the parties. The Amendment revised the economics from a profit-sharing arrangement to a milestone and royalty-based compensation structure to us effective as of April 1, 2013. The Amendment is part of our ongoing restructuring efforts resulting from the voluntary recall announced on February 23, 2013 related to OMONTYS, the suspension of U.S. marketing and promotional activities, and the ongoing investigation with the FDA.
	The Amendment effectuated a transfer of regulatory responsibilities, including the OMONTYS NDA, and all manufacturing, and development responsibilities from us to Takeda. Takeda received a worldwide, exclusive royalty-bearing license under our and joint Takeda-Affymax patents to develop, manufacture and commercialize OMONTYS.
	As a result of the Amendment, Takeda assumed full responsibility for OMONTYS, including the ongoing recall and investigation of OMONTYS as well as any subsequent decisions as to whether the product may be subject to reintroduction if Takeda is able to complete the investigation and address the safety concerns to the satisfaction of the FDA. With the transfer of responsibilities and the NDA, Takeda is responsible for continuing the investigation but there can be no assurance as to when and if a solution will be identified.
	Collaboration revenue reported on our statement of operations consists of the nonrefundable upfront license fees, reimbursement for the sale of API net of costs incurred, net reimbursement of certain development and commercial expenses, revenues from product profit sharing, and milestone payments. We recognized $1.4 million, $94.4 million, and $47.7 million of collaboration revenue during the year ended December 31, 2013, 2012, and 2011, respectively. Of the $1.4 million received in 2013, $0.5 million represented reimbursement for transition personnel assisting in the transfer of regulatory responsibilities to Takeda. The amount receivable from Takeda as of December 31, 2013 and December 31, 2012 was $0.0 million and $18.4 million, respectively.
	Development and Commercialization of OMONTYS in the U.S. Prior to the April 2013 Amendment
	Prior to the Amendment, Takeda bore responsibility for 70% of all third-party expenses related to U.S. development and 50% of all third party expenses related to U.S. commercialization. Certain employee-related expenses supporting the commercialization of OMONTYS in the U.S. were also shared equally.  In addition, costs of certain employees in clinical, regulatory and other development functions supporting any post-marketing development activities such as additional clinical trials required by the FDA as a condition of the approval of OMONTYS in March 2012 or other activities separately agreed to by the parties in the U.S. were shared equally. As part of the Amendment between us and Takeda, both Parties agreed that they will no longer share expenses related to third-party development (70/30 split) and commercialization (50/50 split) as of April 1, 2013. Any expenses incurred by either us or Takeda after April 1, 2013 shall be the responsibility of the respective party and neither Affymax nor Takeda has the right to share expenses with each other.
	In February 2012, as contemplated under the Arrangement, we and Takeda entered into a Co-Promotion Agreement to further specify and formalize terms and conditions relating to the joint U.S. commercialization activities for OMONTYS including a corporate governance structure and division of roles and responsibilities between us and Takeda, including deployment of resources. Prior to the Amendment, we were responsible for deployment of the sales force and the medical affairs field force but shared marketing, account management and payor reimbursement related activities with Takeda. Takeda was responsible for manufacturing and distribution of the finished drug product to the customer and recorded product sales of OMONTYS. Specifically, Takeda had sole responsibility for handling all returns, order processing, invoicing and collection of receivables with regard to sales of OMONTYS. Takeda also had the rights and responsibility for establishing and modifying terms and conditions with respect to the sale of OMONTYS in the U.S., including pricing discounts available to third party payers, price adjustments and other allowable discounts and allowances. In addition, as we and Takeda split profits 50/50 in the U.S., the Co-Promotion Agreement provided further detail relating to the treatment of FTE expenses used to calculate eligible commercial expenses incurred by us and Takeda thereunder. Consistent with the terms of the Arrangement, Takeda retained final decision making authority with respect to terms related to pricing and contracting and responsibility for distribution activities.
	Prior to the Amendment, while Takeda was responsible for the sale of OMONTYS and accordingly Takeda recorded product revenue, we and Takeda shared equally in the net profits and losses of those sales of OMONTYS in the U.S. In determining the OMONTYS net profit or loss, OMONTYS product revenue was reduced by rebates and discounts, cost of goods, and other gross-to-net adjustments incurred by Takeda; royalty expense incurred by us, commercialization expenses (FTE related and out of pocket costs) incurred by both Takeda and us, and certain development costs associated with post-marketing development activities (FTE related and out of pocket costs) incurred by both Takeda and us. We reviewed the revenue, related deductions and expenses provided by Takeda and prepared an invoice to Takeda for our portion of the OMONTYS net profit after factoring in applicable costs incurred by us and Takeda at the end of each quarter. The profit equalization amount was recognized as revenue in the period the product sales occurred and product revenue was recognized by Takeda.
	As a result of the voluntary recall of OMONTYS in February 2013, all marketing activities were suspended. As part of the Amendment with Takeda, the profit equalization revenue for the six months ended June 30, 2013 was the final profit equalization payment under the Arrangement. Upon signing the Amendment with Takeda, the economics of the collaboration changed from a profit sharing arrangement to a milestone and royalty-based compensation structure to us, effective April 1, 2013.
	Development and Commercialization of OMONTYS outside of the U.S.
	In February 2006, we granted an exclusive license to Takeda for development and commercialization of OMONTYS in Japan. In December 2011, Takeda announced that it had decided not to commercialize OMONTYS in Japan. We and Takeda have explored other options for the commercialization rights for OMONTYS in the Japanese market, including potentially licensing it to a third party. If Takeda or its licensee is successful in clinical development and regulatory milestones, we are eligible to receive contingent payments from Takeda which aggregate up to $33.0 million relating to the Japan renal program and $5 million for a third indication that neither we or Takeda is pursuing. Per the terms of the Amendment, the Japan agreement was terminated.
	In June 2006, Takeda subsequently received an exclusive license to develop and commercialize the product outside of the U.S. Takeda bears all costs for product clinical development in support of regulatory approval for all territories outside the U.S. and will pay us a variable royalty based on annual net sales of the product outside the U.S. In February 2012, Takeda announced the acceptance for assessment from the Eupopean Medicines Agency or EMA of a Marketing Authorization Application or MAA for OMONTYS for the treatment of symptomatic anemia associated with chronic kidney disease in adult patients on dialysis.  As a result of the recall of OMONTYS, the MAA application has been withdrawn.
	Launch Allowance
	As noted above, Takeda bore responsibility for 50% of all third party expenses related to the commercialization of OMONTYS in the U.S. Takeda also provided a launch allowance to help fund the initial costs associated with preparing to launch under which it committed to fund the first $20.0 million of U.S. commercial expenses incurred in total by us and Takeda. Amounts received under the launch allowance are non-refundable; under the Amendment, however, Takeda is entitled to deduct up to 8% from any future payments made to us under the royalty or milestone provisions until they have recouped an amount equal to $11.0 million ($10.0 million plus a $1.0 million fixed amount that represents interest). As of December 31, 2013, our liability balance under the launch allowance is $8.2 million.
	Due to voluntary recall of OMONTYS in February 2013, all marketing activities have been suspended and there is no certainty as to when those activities will restart. The launch allowance will remain as a liability until we can determine, if at all, the timing of when that liability will be extinguished or if the collaboration is terminated. If our collaboration with Takeda is terminated prior to Takeda's recoupment of the balance, there is no obligation that we repay these amounts.
	Milestones
	During 2012 we earned the following milestone payments from Takeda, a $50.0 million milestone upon FDA approval of OMONTYS in the dialysis indication, a $5.0 million milestone upon acceptance for review of the MAA, filing for OMONTYS by the EMA, and a $3.0 million and $2.3 million milestone related to an amendment to the Arrangement or the November 2011 Amendment, described below.
	As a result of the Amendment, Takeda assumed full responsibility for OMONTYS, including the ongoing recall and investigation of OMONTYS as well as any subsequent decisions as to whether the product may be subject to reintroduction if Takeda is able to complete the investigation and address the safety concerns to the satisfaction of the FDA. We provided transition support to Takeda through April 30, 2013. After April 30, 2013 we have no performance obligations under our agreement with Takeda. If Takeda decides to reintroduce OMONTYS, all of which is highly uncertain, we are eligible to receive royalties and (i) potential contingent payments in the form of commercial milestone payments totaling up to $180.0 million, which consist of the following: (a) $10.0 million is payable upon the first commercial sale after reintroduction of OMONTYS in the U.S.: (b) $10.0 million and another $10.0 million relates to U.S. sales-based milestones, and (c) $150.0 million relates to sales-based milestones outside of the U.S. as disclosed below but now including Japan as a result of the Amendment and (ii) a potential development milestone payment of $5.0 million payable either upon regulatory approval in the E.U. or Japan. The royalties are tiered in the range of 13% to 17% with respect to net sales in the U.S. and in the range of 13% to 24% depending on the level of net sales by Takeda worldwide outside of the U.S. The $150.0 million of sales-based milestones consists of milestones of $10.0 million, $20.0 million, $30.0 million, $40.0 million and $50.0 million for worldwide net sales reached and recorded by Takeda during a fiscal year of the arrangement of $0.5 billion, $1.0 billion, $1.5 billion, $2.0 billion and $3.0 billion, respectively. Although we are eligible to receive future milestones from Takeda, timing and amounts of future milestone payments, if any, are highly uncertain due to the recall.
	API Supply Agreement
	In November 2011, as contemplated under the Arrangement, we and Takeda executed a Commercial API Supply Agreement. Under the terms of the API Supply Agreement, we were responsible for the manufacture and supply of all quantities of API to be used in the development and commercialization of OMONTYS worldwide. Takeda reimbursed us for our cost of API plus 20%. Takeda was responsible for the fill and finish steps in the manufacture of OMONTYS worldwide under the Arrangement. As of December 31, 2012 we had a balance of $17.8 million recorded as an Advance from Takeda which was related to deferred revenue on API shipped to Takeda. As a result of the recall and the impairment charges recorded on the OMONTYS inventory during 2012, the remaining balance of deferred revenue was reversed as of June 30, 2013.
	Impairment of Inventory and Firm Purchase Commitments
	Prior to the voluntary recall, we initiated orders for API with our CMOs based on forecasts from Takeda, which were based on expected demand for OMONTYS. Orders generally had commenced once there was a contractual commitment for the API from Takeda. In the quarter ended June 30, 2013 we settled these obligations for less than the contractual amounts. We made a total of $11.0 million in payments to settle our obligations to three CMOs and recorded a favorable adjustment to our operating results of $21.9 million.
	In addition to the binding CMO purchase commitments, we also had $10.4 million in inventory and prepayments made to our CMOs on our balance sheet as of December 31, 2012. As a result of the inability to sell OMONTYS and the uncertainty of future revenues, we have written down our API inventory and prepayments for API being produced by our CMOs to a net realizable value of zero and recorded a $10.4 million impairment charge related to this writedown during the year ended December 31, 2012. Of the total $45.0 million charge for impairment of inventory and loss on CMO purchase commitments recorded in 2012, we recorded a benefit of $20.3 million in the first quarter of 2013, primarily related to the collaboration cost reimbursement under the Takeda Q1 profit equalization payment. As a result of the fourth Amendment, Takeda assumed full responsibility for OMONTYS. This includes the ongoing investigation of OMONTYS as well as any subsequent decisions as to whether the product may be subject to reintroduction. Reintroduction would be possible only if Takeda is able to complete the investigation and address the safety concerns to the satisfaction of the FDA.
	Cost of Recall
	As a result of the fourth Amendment, Takeda assumed full responsibility for OMONTYS. This includes the ongoing investigation of OMONTYS as well as any subsequent decisions as to whether the product may be subject to reintroduction. Reintroduction would be possible only if Takeda is able to complete the investigation and address the safety concerns to the satisfaction of the FDA.
	The total costs of recalling the product were primarily composed of costs to a third-party to gather, store, and return the product to Takeda, of which $1.1 million was incurred in the first quarter of 2013. Our portion of the expense was $0.6 million which we were charged as a part of the Q1 profit equalization payment in the first quarter of 2013.
	Takeda capitalizes inventory costs associated with the production of OMONTYS and enters into purchase commitments for goods associated with this manufacturing. The write down or write off of such inventory and any charges for purchase commitments by Takeda was subject to the profit equalization revenue or loss calculation of the Arrangement. Takeda included inventory write down charges of $31.8 million for the cost of inventory on hand at Takeda as of March 31, 2013 in the Q1 profit equalization payment. Our portion of this write down was $15.9 million and was previously reserved for as of December 31, 2012 as a part of our Advance from Takeda liability. With respect to purchase commitments, Takeda requested reimbursement for a portion of the costs associated with Takeda's firm purchase commitment of $9.3 million with Baxter for pre-filled syringes. Our exposure was limited to the portion of the Baxter agreement that relates to the U.S. We had no liability related to the E.U. or Japan because in those countries we receive only a royalty on product sales and the collaboration profit split did not apply to operations in those countries. The amount of our exposure was $0.7 million which was included in the Q1 profit equalization payment in the first quarter of 2013.
	In the first quarter of 2013, Takeda recorded an impairment charge for certain long lived assets associated with OMONTYS.  Under the profit/loss equalization we were responsible for half of these charges.  Our exposure related to this impairment was $6.2 million.  This amount was charged to us as a part of the Q1 profit equalization payment in the first quarter of 2013.
	November 2011 Amendment
	In November 2011, concurrent with the execution of the Settlement and License Agreement with Janssen, we and Takeda entered into an amendment to the Arrangement. Under the terms of this amendment, Takeda agreed to pay up to $6.5 million in additional milestones to us in consideration of the upfront and milestone payments we are required to make to Janssen under the Settlement and License Agreement. Approximately $5.3 million of these milestones were earned based on regulatory and commercial events in the U.S. and the remaining $1.3 million tied to regulatory events in the E.U, which was eliminated as part of the Amendment.  We recognized $3.0 million of these milestones in the first quarter of 2012 as it was earned as a result of FDA approval in March 2012.

Contractual_Arrangements

Contractual Arrangements	12 Months Ended
	Dec. 31, 2013
Settlement and License Agreement [Abstract]	'
Contractual Arrangements	'
	Contractual Arrangements
	Our License, Manufacturing and Supply Agreement with Nektar
	In April 2004, we entered into a License, Manufacturing and Supply Agreement with Nektar Therapeutics AL Corporation, or Nektar, under which we obtained from Nektar a worldwide, non-exclusive license, with limited rights to grant sublicenses, under certain intellectual property covering pegylation technology to manufacture, develop and commercialize OMONTYS. The license we obtained consists of a license under intellectual property owned by Nektar and a sublicense under intellectual property owned by Enzon Pharmaceuticals, Inc., or Enzon, licensed to Nektar pursuant to a cross-license agreement between Nektar, Inhale Therapeutic Systems, Inc. and Enzon.
	In consideration of the license grant, we agreed to pay royalties on the sales of OMONTYS, which began with the launch of the product in the U.S. in 2012 and was suspended on February 26, 2013. We also agreed to pay base milestones plus possible additional milestones in connection with our partnering activities relating to OMONTYS or merger and acquisition activities. As of December 31, 2013 no further milestone obligations remain.
	Contract Manufacturing Organization (CMO) Settlements
	We initiated orders for API with our CMOs based on forecasts from Takeda, which were based on expected demand for OMONTYS. Orders generally commenced once there was a contractual commitment for the API from Takeda. As of December 31, 2012, we had future purchase commitments amounting to $34.6 million. These future commitments were comprised of $5.8 million for firm purchase commitments of PEG, and the remaining $28.8 million of manufacturing obligations relate to API, and were based on firm demand forecasts from Takeda. We paid $1.7 million in payments to our CMOs in our first quarter 2013 which reduced the accrual balance to $32.9 million.
	We finalized settlement agreements with the CMOs in the second quarter of 2013 and made a total of $11.0 million in payments resulting in a favorable adjustment to our second quarter 2013 operating results of $21.9 million.
	Settlement and License Agreement with Janssen
	In November 2011, we entered into the Settlement and License Agreement with Janssen under which we obtained a non-exclusive license to the intellectual property in dispute, a covenant not to sue and a release of all claims associated with the arbitration and dispute. The Settlement and License Agreement also provides for the dismissal of all pending proceedings. The Settlement and License Agreement required us to make two fixed payments to Janssen, $6.0 million, which was paid in December 2011, and $2.0 million, which was paid in June 2012.  Upon execution of the Settlement and License Agreement in the fourth quarter of 2011, we recorded $8.0 million of R&D expense relating to the fixed payments.  The Settlement and License Agreement also required us to make a $2.5 million milestone payment to Janssen upon FDA regulatory approval of OMONTYS, and requires us to make a $2.5 million milestone payment to Janssen upon regulatory approval of OMONTYS in the first major European country. Upon FDA approval in March 2012, we capitalized $2.5 million related to the first milestone payment during the first quarter of 2012 as an other asset. The resulting asset was to be amortized over the expected life of the related patent family, the last-expiring patent of which expires in June 2016. This $2.5 million milestone payment was paid to Janssen in April 2012. For the year ended December 31, 2013, as a result of the recall, we recorded a $1.9 million impairment charge related to this asset, bringing the asset value to zero.
	In addition, Janssen will be entitled to low, single-digit royalties on sales of OMONTYS in Europe, Japan and certain other countries outside of the United States until mid-2016. This royalty payment is not reimbursable under our collaboration with Takeda.

Balance_Sheet_Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Supplemental Balance Sheet Disclosures	'
	Balance Sheet Components
	Property and Equipment, Net
	Property and equipment consist of the following (in thousands):
		December 31,
		2013		2012
	Leasehold improvements	$	—	$	2,501
	Equipment	—		9,794
	Software	—		3,064
	Construction in progress	—		9
		—		15,368
	Less: Accumulated depreciation and amortization	—		(12,387		)
		$	—	$	2,981
	Depreciation and amortization expense for the years ended December 31, 2013, 2012, and 2011, was $0.7 million, $2.0 million, and $2.2 million, respectively. In addition to the expense noted above, we also incurred $1.9 million in impairment charges for the year ended December 31, 2013. In May of 2013 management committed to a plan to sell all of the Company's property and equipment. The assets were classified as held for sale and depreciation expense was recorded through May 15, 2013. The assets were sold in June of 2013 for $1.2 million. The book value of the assets sold was $0.5 million after the impairment charge and a gain of $0.7 million was recorded in the year ended December 31, 2013.
	Accrued Liabilities
	Accrued liabilities consist of the following (in thousands):
		December 31,
		2013		2012
	Accrued potential losses related to firm purchase commitments	$	—	$	34,599
	Restructuring accrual	315		—
	Compensation-related expenses	—		12,837
	SG&A related costs	266		3,633
	R&D related costs	—		830
	Other	—		623
		$	581	$	52,522

Investments

Investments	12 Months Ended
	Dec. 31, 2013
Available-for-sale Securities [Abstract]	'
Investments	'
	Investments
	We held no investments as of December 31, 2013 and there were no realized gains or losses on investments during the years ended December 31, 2013, 2012, or 2011. A summary of our investments outstanding as of December 31, 2012 is as follows (in thousands):
		As of December 31, 2012
		Cost		Gross		Gross			Fair Value
				Unrealized		Unrealized
				Gains		Losses
	Short-term investments:
	Certificates of deposit	$	1,300	$	—	$	—		$	1,300
	Corporate debt securities	8,416		1		—			8,417
	Total short-term investments	$	9,716	$	1	$	—		$	9,717
	Long-term investments:
	Corporate debt securities	$	2,326	$	—	$	(3	)	$	2,323
	Total long-term investments	$	2,326	$	—	$	(3	)	$	2,323

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	We measure certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and available for sale securities.  The fair value of these assets was determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:
	•	Level 1 — observable inputs such as quoted prices in active markets.
	•	Level 2 — inputs other than quoted prices in active markets that are observable either directly or indirectly through corroboration with observable market data.
	•	Level 3 — unobservable inputs in which there is little or no market data, which would require us to develop our own assumptions.
	The types of investments that are generally classified within Level 1 of the fair value hierarchy include money market securities. The valuation technique we used to measure fair value of our Level 1 money market securities is a market approach, using prices and other relevant information generated by market transactions involving identical securities.  The types of investments that are generally classified within Level 2 of the fair value hierarchy include corporate securities, certificates of deposits and U.S. government securities.  The valuation technique we used to measure fair value of our Level 2 investments is a market approach, under which we review trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical investments was not available, we used market pricing and other observable market inputs for similar investments obtained from various third party data providers. These inputs represent quoted prices for similar investments in active markets or these inputs have been derived from observable market data.
	Financial instruments that are not recorded at fair value are measured at fair value on a quarterly basis for disclosure purposes. The fair value of the notes payable are based on the present value of expected future cash flows, assumptions about current interest rates and the creditworthiness of Affymax.
	The carrying amount of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximates fair value due to their relatively short maturities, and low market interest rates if applicable.
	We held no assets or liabilities as of December 31, 2013 which were remeasured to fair value on a recurring basis.
	The following table presents as of December 31, 2012 our investments measured at fair value on a recurring basis classified by the fair value measurements and disclosures valuation hierarchy (in thousands):
		As of December 31, 2012
				Fair Value Measurements Using
		Total		Level 1		Level 2		Level 3
	Money market funds	$	45,999	$	45,999	$	—	$	—
	Short-term investments:
	Certificates of deposit	$	1,300	$	—	$	1,300	$	—
	Corporate debt securities	8,417		—		8,417		—
	Total short-term investments	$	9,717	$	—	$	9,717	$	—
	Long term investments:
	Corporate debt securities	$	2,323	$	—	$	2,323	$	—
	Total long-term investments	$	2,323	$	—	$	2,323	$	—

Loan_and_Security_Agreement

Loan and Security Agreement	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Loan and Security Agreement	'
	Loan and Security Agreement
	In March 2012, we entered into a loan and security agreement, or the Loan Agreement, with Oxford Finance LLC and Silicon Valley Bank, or, collectively, the Lenders, under which we borrowed $10.0 million.
	On April 3, 2013, we entered into a Letter Agreement, under which (i) we paid all amounts due and owing so as to discharge our obligations thereunder which totaled $9.8 million including remaining principal, interest, final payment and prepayment fees, (ii) we waived any rights to seek additional credit extensions or unfunded commitments under the Loan Agreement, and (iii) the security interest granted to Lenders relating to substantially all of our assets, other than our intellectual property, was terminated. As of December 31, 2013 we had no remaining notes payable outstanding.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Operating Leases
	In June 2013 we moved our remaining four employees into offices in Cupertino, California and vacated all of our facilities in Palo Alto, California. The lease expires in July 2014.
	Rent expense for the years ended December 31, 2013, 2012, and 2011 was $1.8 million, $3.6 million and $3.2 million, respectively. We recognize rent expense on a straight-line basis over the lease period.
	Future minimum payments under non-cancelable lease obligations as of December 31, 2013 are as follows (in thousands):
	2014	23
	Total minimum lease payments	$	23
	Legal Proceedings
	Shareholder Litigation
	On February 27, 2013, a securities class action complaint was filed in the United States District Court for the Northern District of California, naming as defendants the Company, certain of its officers, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc. and Takeda Global Research & Development Center, Inc. A second complaint naming the same defendants was filed on March 6, 2013. On May 2, 2013, the securities class action complaint that was filed on February 27, 2013 was voluntarily dismissed by the plaintiff.  On May 21, 2013, the Court appointed a lead plaintiff in the remaining securities class action complaint that had been filed on March 6, 2013.  On July 22, 2013, a consolidated amended class action complaint was filed on behalf of purported stockholders of the Company, naming as defendants the Company and certain of its former officers.  The consolidated amended complaint alleges violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, in connection with allegedly false and misleading statements made by the defendants regarding OMONTYS, the Company's business practices, financial projections and other disclosures between August 8, 2012 and February 22, 2013, or the Class Period.  The plaintiff seeks to represent a class comprised of purchasers of the Company's common stock during the Class Period and seeks damages, costs and expenses and such other relief as determined by the Court.  On September 20, 2013, the Company and the individual defendants (collectively, “Defendants”) filed a motion to dismiss the consolidated amended complaint.  On November 19, 2013, the plaintiff filed her opposition to the motion to dismiss and on December 19, 2013, Defendants filed their reply in support of their motion to dismiss.  The hearing on the motion to dismiss occurred on January 15, 2014.  On January 21, 2014, the Court issued its order granting the motion to dismiss regarding violations of Section 20(a) against all Defendants and it granted the motion to dismiss in part, denying the motion to dismiss in part, and providing plaintiffs with an opportunity to amend the complaint.   On February 18, 2014, the Court, pursuant to a stipulation by the parties, stayed the litigation for ninety days to allow the parties to conduct settlement discussions.
	On March 19, 2013 and March 29, 2013, respectively, two derivative lawsuits were filed purportedly on behalf of the Company in California Superior Court for the County of Santa Clara naming certain of our current and former officers and directors as defendants (the “State Court Derivative Action”). The lawsuits allege that certain of the Company's officers and directors breached their fiduciary duties related to the clinical trials for OMONTYS and for representations regarding the Company's business health, which was tied to the success of OMONTYS. The lawsuits also assert claims for unjust enrichment and corporate waste.  On May 31, 2013, the Court consolidated the two actions and appointed lead plaintiff.  On June 11, 2013, lead plaintiff designated the complaint filed on March 29, 2013 as the operative complaint. On August 6, 2013, the Court stayed the State Court Derivative Action pending the outcome of the motion to dismiss in the securities class action.  Subsequent to the order regarding the motion to dismiss in the securities class action, on January 31, 2014, the Court ordered that the State Court Derivative Action be stayed in its entirety until resolution of the securities class action.
	.
	On August 19, 2013, another derivative lawsuit was filed purportedly on behalf of the Company in the United States District Court for the Northern District of California naming certain of our current and former officers and directors as defendants (the “Federal Derivative Action”). The lawsuit’s allegations are substantially similar to the allegations in the State Court Derivative Action. On October 21, 2013, the Court ordered a stay in the Federal Derivative Action pending the outcome of the motion to dismiss in the securities class action.  Subsequent to the order regarding the motion to dismiss in the securities class action, on January 31, 2014, the Court ordered that the Federal Derivative Action be stayed until resolution of the securities class action.
	Additional complaints may be filed against us and our directors and officers related to our recall of OMONTYS.
	Product Liability Litigation
	On or about February 13, 2014, a complaint was filed by an individual plaintiff in the Fourth Judicial District Court (Ouachita Parish) of the State of Louisiana, naming as defendants the Company, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals U.S.A., Inc., Takeda Development Center Americas, Inc., Takeda Pharmaceuticals International, Inc., Takeda Pharmaceutical Company Limited, Fresenius Medical Care Monroe, LLC, and Fresenius Medical Care Holdings, Inc., and indicating an intention to add two physicians as defendants.  The plaintiff seeks to hold the defendants liable in connection with the death of her husband on February 15, 2013.  The complaint alleges that the Company and certain other defendants are liable under the Louisiana Products Liability Act, La.R.S. 9:2800.51, et seq., other Louisiana statutes, and otherwise in connection with their alleged acts and omissions with respect to OMONTYS.  The plaintiff seeks various categories or types of damages, including, without limitation, damages for her and her late husband’s alleged losses and injuries, punitive or exemplary damages, the price of OMONTYS and reasonable expenses occasioned by the sale of that drug, and other relief as set forth in the complaint.  We are continuing to review the complaint with our partner, Takeda and there can be no assurances that additional product liability complaints will not be brought.
	Our management believes that we have meritorious defenses and intends to defend these lawsuits vigorously. However, these lawsuits are subject to inherent uncertainties, the actual cost may be significant, and we may not prevail. We believe we are entitled to coverage under our relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.
	We assess litigation to determine if an unfavorable outcome would lead to a probable loss or reasonable possible loss, which could be estimated.  We accrue for losses that are both probable and reasonably estimable. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.  In the cases where we believe that a reasonable possible loss exists, we disclose the facts and circumstances of the litigation, including an estimable range, if possible.  Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonable possible loss. Accordingly, no loss accrual has been established for the above.  While it is not possible to accurately predict or determine the eventual outcome of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our financial condition, results of operations or cash flows.

Stockholders_Equity

Stockholder's Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholder's Equity	'
	Stockholder's Equity
	Preferred Stock
	Our Certificate of Incorporation, as amended and restated in December 2006, designates and authorizes 10,000,000 shares of $0.001 par value preferred stock, none of which were issued and outstanding as of December 31, 2013 and 2012. The rights, preferences and privileges of any preferred stock to be issued pursuant to our current Certificate of Incorporation, as amended and restated, have yet to be established.
	No dividends on preferred stock have been declared since inception through December 31, 2013.
	Common Stock
	Our Certificate of Incorporation authorizes us to issue 100,000,000 shares of $0.001 par value common stock. As of December 31, 2013, and 2012, respectively we had 37,490,095 and 37,369,717 shares of common stock issued and outstanding.
	No dividends on common stock have been declared since inception through December 31, 2013.
	Warrants
	Warrants to purchase an aggregate of 423,971 shares of common stock, at an exercise price of $16.78 per share, were issued in March 2009, which was related to a private placement. The warrants expired on March 2, 2014.
	Equity Incentive Plans
	2001 Stock Option/Stock Issuance Plan
	In September 2001, we adopted the 2001 Stock Option/Stock Issuance Plan or the 2001 Plan. The 2001 Plan provides for both the granting of stock options and issuing shares of stock to our employees and consultants. Stock options granted under the 2001 Plan may be either incentive stock options or nonqualified stock options. Incentive stock options or ISOs, may be granted only to our employees. Nonqualified stock options or NSOs, may be granted to our employees, directors and consultants. Stock options under the 2001 Plan may be granted with a maximum life of 10 years and at prices no less than the fair market value for ISOs and 85% of the fair market value for NSOs, as determined by the Board of Directors. The exercise price of an ISO or NSO granted to an individual that holds 10% or more of our outstanding stock shall not be less than 110% of the estimated fair value of the shares on the date of grant. To date, stock options granted generally become exercisable over four years. We issue new shares of common stock upon exercise of stock options.
	2006 Equity Incentive Plan
	Upon the effectiveness of our initial public offering in December 2006, we adopted the 2006 Equity Incentive Plan, which was amended and restated in June 2012, or the 2006 Plan. Shares of common stock issuable pursuant to all then outstanding stock awards granted under the 2001 Plan remained subject to the terms of the 2001 Plan and no additional stock awards were granted pursuant to the terms of the 2001 Plan upon the effective date of the 2006 Plan.
	The 2006 Plan provides for both the granting of stock awards, including stock options and RSUs, to our employees, directors and consultants. Stock options granted under the 2006 Plan may be either ISOs or NSOs. ISOs may be granted only to our employees. NSOs may be granted to our employees, directors and consultants. Stock options under the 2006 Plan may be granted with a maximum life of 10 years and at prices no less than the fair market value of our common stock on the date of grant. The exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the fair market value of our common stock on the date of grant. To date, stock options granted generally become exercisable over four years and do not allow for the early exercise of options prior to vesting. The terms of the RSUs granted by us to date provide for vesting and delivery of shares of common stock generally over three years or are subject to performance based vesting upon milestones (described below). As of December 31, 2013, we reserved 8,308,443 shares of common stock for issuance under the 2006 Plan.
	Under the 2006 Plan, we issue new shares of common stock upon exercise of stock options. The number of shares of common stock reserved for issuance automatically increases on January 1st of each year, from January 1, 2007 through January 1, 2016, by the lesser of (a) 4.5% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (b) 1,400,000 shares. The maximum number of shares that may be issued pursuant to the exercise of incentive stock options under the 2006 Plan is equal to the total shares reserved, as increased from time to time pursuant to annual increases and shares subject to options granted pursuant to the 2001 Plan that have expired without being exercised in full.
	As a result of the OMONTYS recall and subsequent reduction in force of almost all personnel the majority of outstanding options were forfeited and returned to the plan in 2013. The only participants in the plan include Board members and the remaining employees. There were 4,906,238 total shares available for grant, combined, under the 2001 and 2006 Plans as of December 31, 2013.
	2006 Employee Stock Purchase Plan
	Upon the effectiveness of our initial public offering in December 2006, we adopted the 2006 Employee Stock Purchase Plan or the Purchase Plan. As a result of the OMONTYS recall and subsequent reduction in force of almost all personnel the Board of Directors elected in May 2013 to terminate future offerings under the Employee Stock Purchase Plan. For the year ended December 31, 2013, 2012, and 2011, 0, 224,908 and 184,382 shares of common stock, respectively, were purchased under the Purchase Plan.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	Stock-Based Compensation
	During the year ended December 31, 2013, we terminated substantially all of our employees. Upon termination, the difference between the expected forfeiture rate and the actual forfeiture rate was adjusted in the recognition of the stock-based compensation, and resulted in an offset to expense for some groups of employees. Stock-based compensation was recorded in the statements of operations as follows (in thousands):
		Year ended December 31,
		2013				2012				2011
	Research and development	$	878			$	4,324			$	4,632
	Selling, general and administrative	3,564				6,887				5,393
	Total	$	4,442			$	11,211			$	10,025
	We granted the following stock options and RSUs to employees and directors as follows:
		Year ended December 31,
		2013							2012					2011
		Number of			Weighted-				Number of			Weighted-		Number of	Weighted-
		Shares			Average Grant				Shares			Average Grant		Shares	Average Grant
					Date Fair Value							Date Fair Value			Date Fair Value
					Per Share							Per Share			Per Share
	Stock options	888,778			$	15.79			2,142,286			$	8.26	1,110,924	$	4.41
	Restricted stock units	393,195			$	16.36			184,963			$	7.99	220,856	$	6.96
	As of December 31, 2013, there was unrecognized compensation cost of $2.4 million related to these stock options and RSUs. The unrecognized compensation cost as of December 31, 2013 is expected to be recognized over a weighted-average amortization period of 1.8 years.
	Valuation assumptions and expense recognition
	We estimate the fair value of employee and director stock options using the Black-Scholes valuation model. The fair value of employee and director stock options is amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee and director stock options was estimated using the following weighted-average assumptions for the years ended December 31, 2013, 2012, and 2011:
		Year ended December 31,
		2013			2012			2011
	Expected volatility	120	%		81	%		80	%
	Risk-free interest rate	0.77	%		0.89	%		1.86	%
	Dividend yield	0	%		0	%		0	%
	Expected term (in years)	5.4			5.5			5.6
	The expected term of stock options represents the average period the stock options are expected to remain outstanding. For the year ended December 31, 2013, the expected term was based on our historical information on employee exercise and post-vesting employment termination behavior. For the years ended December 31, 2012 and 2011, the expected term was based on the expected terms for industry peers as we did not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. The expected stock price volatility for our stock options for the year ended December 31, 2013 was based on our historical volatility of our common stock. The expected stock price volatility for our stock options for the years ended December 31, 2012 and 2011 was determined by examining the historical volatilities for industry peers and using an average of the historical volatilities of our industry peers as we did not have any significant trading history for our common stock. Industry peers consist of several public companies in the biopharmaceutical industry similar in size, stage of life cycle and financial leverage. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of our stock options. The expected dividend assumption is based on our history and expectation of dividend payouts.
	We measured the fair value of RSUs using the closing price of our stock on the grant date. The fair value of RSUs is being amortized on a straight-line basis over the requisite service period of the awards.
	We estimated the fair value of employee stock purchase rights granted under the Purchase Plan using the Black-Scholes valuation model. The weighted-average fair value of each stock purchase right for the years ended December 31, 2013, 2012, and 2011 was $0.00, $4.36 and $2.63 per share, respectively. As a result of the OMONTYS recall and subsequent reduction in force of almost all personnel the Board of Directors elected in May 2013 to terminate future offerings under the Employee Stock Purchase Plan. There were no purchases in 2013. The fair value of employee stock purchase rights were estimated using the following assumptions for the years ended December 31, 2013, 2012 and 2011:
		Year ended December 31,
		2013		2012		2011
	Expected volatility	—%		50%-106%		50%-157%
	Risk-free interest rate	—%		0.04%-0.57%		0.04%-1.00%
	Dividend yield	—%		—%		—%
	Expected term (in months)	—		24-Jun		24-Jun
	The expected term of employee stock purchase rights represents the period the employee stock purchase rights are expected to remain outstanding. The Purchase Plan permits eligible employees to purchase common stock at 6 month intervals at a discount through payroll deductions during defined offering periods. The expected stock price volatility for the years ended December 31, 2012 and 2011 was determined by examining the historical volatilities for industry peers and using an average of the historical volatilities of our industry peers as we did not have any significant trading history for our common stock. Industry peers consist of several public companies in the biopharmaceutical industry similar in size, stage of life cycle and financial leverage. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of our employee stock purchase rights. The expected dividend assumption is based on our history and expectation of dividend payouts.
	There were no tax benefits related to employee stock-based compensation for the years ended December 31, 2013, 2012, and 2011.
	Stock Option and Restricted Stock Unit Activity
	The following tables summarize information about stock option and RSU activity for the year ended December 31, 2013:
		Number of			Weighted-				Weighted-		Aggregate
		Shares			Average Exercise Price				Average		Intrinsic Value
					(Per Share)(1)				Remaining		(in thousands)(2)
									Contractual
									Term
									(in years)
	Stock Options:
	Balances at December 31, 2012	4,857,536			$	13.49
	Granted	888,778			18.83
	Exercised (3)	(30,918	)		8.77
	Forfeited	(2,889,025	)		13.35
	Cancelled	(986,514	)		13.74
	Balances at December 31, 2013	1,839,857			$	16.24			3.56		$	—
	Options exercisable at	1,551,929			$	17.06			2.76		$	—
	31-Dec-13
	Options vested and expected to vest at December 31, 2013	1,834,691			$	16.24			3.55		$	—
		Number of			Weighted-				Weighted-			Aggregate
		Shares			Average Grant Date Fair Value				Average			Intrinsic Value
					(Per Share)(1)				Remaining			(in thousands)(2)
									Contractual
									Term
									(in years)
	Restricted Stock Units:
	Balances at December 31, 2012	296,723			$	7.54
	Granted (time-based)	393,195			16.36
Vested	(89,460	)		7.58
Forfeited	(600,458	)		—
Balances at December 31, 2013	—			$	—			—			$	—
_______________________________________________________________________________
-1	The weighted average price per share is determined using exercise price per share for stock options and fair value per share on grant date for restricted stock units.
-2	The aggregate intrinsic value is calculated as:
•	For options: the difference between the exercise price of the option and the fair value of our common stock for in-the-money options at December 31, 2013.
•	For restricted stock units: the difference between the grant date fair value of the unit and the fair value of our common stock for in-the-money units at December 31, 2013.
-3	The total intrinsic value of stock options exercised was $0.3 million, $10.6 million, and $0.3 million during the years ended December 31, 2013, 2012, and 2011, respectively, and was determined at the date of each exercise.
During 2010, the Board of Directors approved the grant of 225,000 performance-based RSUs, or PRSUs, to certain executive officers. These units vest 50% upon FDA acceptance of our NDA submission for review for OMONTYS and 50% upon product launch of OMONTYS. During 2011, 50% of these units vested when the FDA accepted our submission and filed the NDA for review. During 2012, the remaining 50% of these units vested upon product launch of OMONTYS.
The total fair value of stock options that vested during the years ended December 31, 2013, 2012 and 2011 was $3.2 million, $6.2 million and $7.2 million, respectively. The total fair value of RSUs and PRSUs that vested during the years ended December 31, 2013, 2012 and 2011 was $0.1 million, $0.8 million and $0.9 million, respectively.
The stock options outstanding and exercisable by exercise price at December 31, 2013 are as follows:
	Stock Options Outstanding							Stock Options Exercisable
Range of Exercise Prices	Number of			Weighted-		Weighted-		Number of			Weighted-
	Shares			Average		Average		Shares			Average
				Remaining		Exercise					Exercise
				Contractual		Price Per Share					Price Per Share
				Life in Years
$0.80 - 10.99	728,358			8.21		$7.31		542,799			$7.32
$11.00 - 20.22	417,558			8.12		$16.87		333,921			$16.23
$20.23 - 32.89	583,246			6.81		$23.56		564,509			$23.59
$32.90 - 33.97	110,700			3.78		$33.97		110,700			$33.97
$0.80 - 33.97	1,839,862			7.73		$16.23		1,551,929			$17.06
Deferred Stock-Based Compensation
In September 2003, we approved the repricing of existing employee stock options from $4.00 to $0.80 per share, which was deemed to be the fair market value. As a result of the repricing, stock options are subject to variable accounting. At December 31, 2013, no repriced stock options remained outstanding. During the years ended December 31, 2013, 2012, and 2011, we have recorded deferred stock-based compensation (benefit) related to these stock options of $(3,000), $87,000, and $(5,000), respectively, and recorded stock-based compensation (income) expense of $(3,000), $87,000, and $(5,000), respectively.
Nonemployee Stock-Based Compensation
Stock-based compensation expense related to stock options granted and common stock issued to nonemployees is recognized as the stock options are earned. We believe that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. The fair value of stock options granted to nonemployees is calculated at each grant date and remeasured at each reporting date. The stock-based compensation expense related to a grant will fluctuate as the fair value of our common stock fluctuates over the period from the grant date to the vesting date. There were no stock options granted to nonemployees or related expense recorded in 2013. We recorded nonemployee stock-based compensation (benefit) expense of $1,000, $69,000, and $(10,000), respectively, for the years ended December 31, 2013, 2012, and 2011.

Restructuring_Charge

Restructuring Charge	12 Months Ended
	Dec. 31, 2012
Restructuring and Related Activities [Abstract]	'
Restructuring Charge	'
	Restructuring Charge
	2011 Restructuring
	As a result of a May 2010 amendment to our operating lease, we took possession of approximately 16,000 square feet of additional office space adjacent to our corporate headquarters in Palo Alto, California in May 2011.  During the year ended December 31, 2011, management concluded that we would not occupy this additional office space.  Given these plans and the fact that this space is adequately separable from our existing facilities, we recorded total restructuring charges of $869,000 during the year ended December 31, 2011, which represents the present value of the estimated future facility costs for which we expected no future economic benefit over the term of our lease, net of estimated future sublease income. The $869,000 charge, as well as $72,000 of accretion was recorded during the year ended December 31, 2011 in SG&A expenses in the statement of operations.
	The estimates underlying the fair value of the lease-related restructuring liability involved significant assumptions regarding the time required to contract with a subtenant, the amount of space we would be able to sublease, the range of potential sublease rates and the level of leasehold improvement expenditures that would be incurred to sublease the property.
	In March 2012, we entered into a sublease agreement with a third party to sublease approximately 8,000 of the 16,000 square feet of the available office space.  The sublease originally had a twenty-eight month term that began on May 1, 2012 and ended on August 31, 2014. This sublease was terminated along with our operating lease termination in 2013.  In March 2012, management concluded that the remaining excess office space could not effectively be sub-leased due to the sublease of only a portion of the broader space, prevailing market conditions, and our assessment of the marketability of the remaining space given the size and remaining term.  As a result of this determination, and due to other developments in our operations, management elected to reconfigure the remaining space to make it available for use by the Company as needed.  As a result, we reversed a net amount of $336,000 relating solely to the new sublease and the related space during the three months ended March 31, 2012.
	In August of 2011, we initiated a restructuring plan to lower annual operating expenses that included a planned reduction in force of 22 positions.
	The following table summarizes the accrual balance and utilization by type for the 2011 restructuring (in thousands):
		Facilities			Employee			Total
		Related			Related
	Balance as of January 1, 2011	$	—		$	—		$	—
	Restructuring charge accrued	869			975			1,844
	Cash payments	-431			-710			-1,141
	Accretion	72			—			72
	Balance as of January 1, 2012	510			265			775
	Restructuring charge accrued	77			6			83
	Adjustments	(413		)	(62		)	(475		)
	Cash payments	(214		)	(209		)	(423		)
	Accretion	11			—			11
	Balance as of December 31, 2012	(29		)	—			(29		)
	Adjustments	29			—			29
	Balance at December 31, 2013	$	—		$	—		$	—
	2013 Restructuring
	On February 23, 2013, we and Takeda announced a nationwide voluntary recall of OMONTYS as a result of post marketing reports regarding safety concerns, including anaphylaxis, which can be life-threatening or fatal. As a result of the voluntary recall of OMONTYS, all marketing activities were suspended and we have also suspended or terminated manufacturing activities.
	In March 2013, we began implementing plans to restructure our operations in order to reduce operating costs and focus on the OMONTYS safety and other related FDA issues associated with the recall of the product. As of June 30, 2013, in addition to transitioning many of the ongoing activities to our collaborator, Takeda, we completed a reduction in force of almost all our personnel, including all of our commercial and medical affairs field forces as well as other employees throughout the organization.  We have recorded $16.1 million in restructuring charges related to the workforce reduction and facilities during the year ended December 31, 2013.
	The following table summarizes the accrual balance and utilization by type for the 2013 restructuring (in thousands):
		Facilities			Employee			Total
		Related			Related
	Balance as of December 31, 2012	$	—		$	—		$	—
	Restructuring charges accrued	2,500			14,766			17,266
	Adjustments	—			(1,200		)	(1,200		)
	Cash payments	(2,500		)	(13,251		)	(15,751		)
	Balance at December 31, 2013	$	—		$	315		$	315

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The components of the provision for income taxes are as follows (in thousands):
		Year ended December 31,
		2013				2012				2011
	Provision (benefit) for income taxes:
	Current provision (benefit) for income taxes:
	Federal	$	(26	)		$	(27	)		$	—
	State	(2,132		)		1				1
	Total current provision (benefit) for income taxes	(2,158		)		(26		)		1
	Deferred tax benefit:
	Federal	—				—				—
	State	—				—				—
	Total deferred tax benefit	—				—				—
	Provision (benefit) for income taxes	$	(2,158	)		$	(26	)		$	1
	We recorded a provision for minimum statutory state tax and provided no federal tax as a result of our net operating loss for the year ended December 31, 2013, 2012 and 2011. For the year ended December 31, 2013, a tax benefit was recognized due to changes in uncertain tax positions.
	We incurred significant operating losses since inception and anticipate that we may incur continued losses in the future.
	A reconciliation of the federal statutory income tax rate to our effective income tax rate is as follows:
		Year ended December 31,
		2013			2012			2011
	Federal statutory income tax rate	(35.00	)%		(35.00	)%		(35.00	)%
	State income taxes, net of federal benefit	(12.85	)		—			—
	Stock-based compensation expense	9.76			3.04			4.15
	Change in valuation allowance	(7.89	)		32.52			(56.26	)
	Change in federal rates and prior year true ups	32.81			(0.64	)		0.7
	Permanent differences	0.32			0.08			0.08
	Tax credits	—			—			2.66
	Changes in tax reserves	(0.15	)		(0.03	)		—
	Impairment of tax attributes due to ownership change	—			—			83.67
	Provision (benefit) for income taxes	(13.00	)%		(0.03	)%		0	%
	Deferred tax assets consist of the following (in thousands):
		December 31,
		2013				2012
	Net operating loss carryforwards	$	138,165			$	113,956
	Federal and State credit carryforwards	4,263				4,249
	Depreciation and amortization	8,174				11,866
	Capitalized start-up costs	1,037				1,185
	Accrued liabilities and allowances	6,694				35,955
	Gross deferred tax assets	158,333				167,211
	Deferred tax liability	—				—
	Net deferred tax asset	158,333				167,211
	Less: Valuation allowance	(158,333		)		(159,971		)
	Net deferred tax assets	$	—			$	7,240
	Management establishes a valuation allowance for those deductible temporary differences when it is more likely than not that some or all of the benefit of such deferred tax assets will not be recognized. The ultimate realization of deferred tax assets is dependent upon our ability to generate taxable income during the periods in which the temporary differences are deductible. Management considers the historical level of taxable income, projections for future taxable income, taxable income in carryback years and tax planning strategies in making this assessment. Management's assessment in the near term is subject to change if estimates of future taxable income during the carryforward period are increased. The valuation allowance decreased $1.6 million during the year ended December 31, 2013 and increased $35.4 million during the year ended December 31, 2012. As of December 31, 2013 and 2012, we have a net deferred tax asset balance of $0.0 million and $7.2 million, respectively. The balance at December 31, 2012 represents the net operating loss carryforward that was available to settle the uncertain tax position in liability for the same amount.  In 2013, the company adopted FASB Accounting Standards Update No. 2013-11 to present the liability as an offset to the deferred tax assets.  The adoption has no impact on the income statement of the Company.  We have incurred significant operating losses since inception and anticipate that we may incur continued losses in the future.
	Prior to 2013, we have experienced ownership changes as defined by Sections 382 and 383 of the Internal Revenue Code which establishes an annual limit on the deductibility of pre-ownership change net operating loss or NOL and credit carryforwards. Accordingly, we had reduced our gross deferred tax asset for the expiring carryforwards by $59.6 million as of December 31, 2011. Due to our announcement of our voluntary recall of OMONTYS in February 2013, there has been an extremely high volume of trading of our stock and a significant drop in the value of our stock. As a result of the high trading volume, there was likely a shift of ownership amongst our 5% stockholders that could result in an ownership change, under Section 382 of the Internal Revenue Code. This has likely resulted in an significant impairments of our NOLs and potential elimination of our deferred tax asset which is currently subject to a full valuation allowance. We are currently in the process of assessing the impact.
	At December 31, 2013, we had federal and state net operating loss carryforwards of $481.0 million and $491.0 million, respectively. The federal net operating loss carryforwards begin to expire in 2028 and state net operating loss carryforwards begin to expire in 2018, if not utilized. At December 31, 2013, we had federal and state research credit carryforwards of $9.0 million and $7.0 million, respectively. The federal credits begin to expire, if not utilized, in 2022 and state credits are carried forward indefinitely.
	If our assumptions change and we determine we will be able to realize these net operating losses, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets as of December 31, 2013, will be accounted for as follows: approximately $5.1 million will be recorded as an increase in equity, while the remaining benefit will be recognized as a reduction of income tax expense. Our policy is to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary. For the years ended December 31, 2013, 2012, and 2011, we recognized $(667,000), $(322,000), and $144,000, respectively, of interest (benefit) expense related to our liability for uncertain income tax positions. As of December 31, 2013 and 2012, we had accrued $0 and $664,000, respectively, of interest expense related to our liability for uncertain income tax positions. For the years ended December 31, 2013, 2012, and 2011, there were no penalties related to uncertain income tax positions. We do not anticipate that any of the unrecognized tax benefits will increase or decrease significantly over the next twelve months.
	We record liabilities related to uncertain tax positions in accordance with the guidance that clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements. The guidance prescribes a minimum recognition threshold and measurement process for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We do not believe any such uncertain tax positions currently pending will have a material adverse effect on our financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period. We had $70.9 million, $73.0 million, and $70.6 million of unrecognized tax benefits as of December 31, 2013, 2012, and 2011, respectively.
	As of December 31, 2013 and 2012, $70.9 million and $65.8 million, respectively of the unrecognized tax benefits would affect our income tax provision and effective tax rate if recognized. However, as we would currently need to increase the valuation allowance for any additional amounts benefited, the effective tax rate would not be impacted until the valuation allowance was removed.
	A reconciliation of the unrecognized tax benefits for the years ended December 31, 2013, 2012, and 2011, is as follows (in thousands):
		December 31,
		2013				2012				2011
	Balance at beginning of year	$	73,017			$	70,613			$	13,100
	Additions for current year tax positions	—				—				59,419
	Additions for prior year tax positions	—				2,437				—
	Reductions for statute of limitations	(1,825		)		(27		)		—
	Reductions for prior year tax positions	(338		)		(6		)		(1,906		)
	Balance at end of year	$	70,854			$	73,017			$	70,613
	We file federal and California income tax returns. For U.S. federal and California income tax purposes, the statute of limitation with regards to all returns remains open due to carryforward of net operating losses and R&D credits generated in prior years. There are no tax years under examination by any jurisdiction at this time.

Retirement_Savings_Plan

Retirement Savings Plan	12 Months Ended
	Dec. 31, 2013
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]	'
Retirement Savings Plan	'
	Retirement Savings Plan
	As a result of the OMONTYS recall and subsequent reduction in force of almost all personnel the Board of Directors elected in May 2013 to terminate the company 401K plan. Our contributions to the 401(k) plan were $0, $895,000, and $407,000, for the years ended December 31, 2013, 2012, and 2011, respectively.

Quarterly_Financial_Data

Quarterly Financial Data	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Data	'
	Quarterly Financial Data (unaudited)
	The following tables summarize the unaudited quarterly financial data for the last two fiscal years (in thousands, except per share data):
		2013 Quarter Ended
					March 31,
	Unaudited quarterly financial data	As reported			Revisions (a)			As Revised (a)			June 30,			September 30,			December 31,
	Collaboration revenue	$	839		$	—		$	839		$	525		$	—		$	—
	Total revenue	844			—			844			525			—			—
	Research and development	9,736			53			9,789			2,235			(166		)	(1		)
	Selling, general and administrative	24,346			318			24,664			528			1,886			451
	Income (loss) from operations	(26,196		)	(371		)	(26,567		)	14,271			(1,692		)	(1,058		)
	Net income (loss)	(26,674		)	(371		)	(27,045		)	15,372			(1,692		)	(1,059		)
	Basic net income (loss) per common share	$	(0.71	)	$	(0.01	)	$	(0.72	)	$	0.41		$	(0.05	)	$	(0.03	)
	Weighted-average number of common shares used in computing basic net income (loss) per common share calculation	37,469			—			37,469			37,490			37,490			37,490
	Diluted net income (loss) per common share	$	(0.71	)	$	(0.01	)	$	(0.72	)	$	0.41		$	(0.05	)	$	(0.03	)
	Weighted-average number of common shares used in computing diluted net income (loss) per common share calculation	37,469			—			37,469			37,495			37,490			37,490
	Unaudited balance sheet data							March 31, 2013			June 30, 2013			September 30, 2013
	Additional paid in capital (revised) (Note a)							$	555,947		$	554,509		$	555,007
	Accumulated deficit (revised) (Note a)							$	(570,387	)	$	(554,219	)	$	(555,911	)
	(a) During the fourth quarter of 2013, an error was identified in the unaudited financial statements for the first quarter of 2013 related to the accounting for our former employee stock purchase plan (ESPP). We incorrectly accounted for the termination and cancellation of awards under the ESPP plan related to the significant reduction of our headcount during that period. We evaluated the materiality of the error from a quantitative and qualitative perspective, and concluded that the error was not material to the unaudited financial statements for the three-month period ended March 31, 2013, the six-month period ended June 30, 2013, or the nine-month period ended September 30, 2013. Although the error was not material, we have elected to correct the error by recording an adjustment of $371,000 in the first quarter of 2013 to increase the expense in that period for cancellations of awards, net of adjustments to reverse the unvested compensation expense which had previously been recorded for awards which were forfeited. Of this total adjustment, $53,000 related to research and development expenses and $318,000 related to selling, general and administrative expenses. The correction also increased the previously reported adjustment to reconcile net (loss) income to net cash used in operating activities related to share-based compensation expense in the unaudited statements of cash flows by $371,000 for the three-month period ended March 31, 2013, the six-month period ended June 30, 2013, and the nine-month period ended September 30, 2013. The total of cash used in operating activities in these periods was not affected by the correction.
		2012 Quarter Ended
		March 31,			June 30,			September 30,			December 31,
	Collaboration revenue	$	63,205		$	2,754		$	13,603		$	14,796
	Total revenue	63,209			2,755			13,607			14,799
	Loss from operations	31,520			(31,381		)	(23,990		)	(68,188		)
	Net loss	31,453			(31,956		)	(24,638		)	(68,271		)
	Basic net income (loss) per common share	$	0.88		$	(0.89	)	$	(0.68	)	$	(1.85	)
	Weighted-average number of common shares used in computing basic net income (loss) per common share calculation	35,772			36,075			36,350			36,846
	Diluted net income (loss) per common share	$	0.87		$	(0.89	)	$	(0.68	)	(1.85		)
	Weighted-average number of common shares used in computing diluted net income (loss) per common share calculation	36,338			36,075			36,350			36,846

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash and cash equivalents are stated at cost, which approximates market value. We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Restricted Cash	'
	Restricted Cash
Revenue Recognition	'
	Revenue Recognition
	Collaboration Revenue
	We recognize revenue for contracts entered into prior to 2011 in accordance with the SEC Staff Bulletin No. 101, Revenue Recognition in Financial Statements, as amended by Staff Accounting Bulletin or SAB, No. 104, Revision of Topic 13 and Accounting Standards Codification or ASC, 605-25, Multiple Element Arrangements.  When evaluating multiple element arrangements, we consider whether the components of the arrangement represent separate units of accounting as defined in the authoritative guidance for revenue arrangements with multiple deliverables. Application of this guidance requires subjective determinations and requires management to make judgments about the fair value of the individual elements and whether such elements are separable from the other aspects of the contractual relationship. We continue to follow the guidance of ASC 605-25 to determine whether the components of the Arrangement represent separate units of accounting.  To determine if a delivered item can be treated as a separate unit of accounting, we evaluate (1) if the delivered item(s) has value to Takeda on a standalone basis; (2) there is objective and reliable evidence of fair value of the undelivered item(s) and (3) if a general right of return exists for the delivered item (e.g. contingencies), delivery or performance of the undelivered item(s) is considered probable and is substantially within the control of the company.  We recognize revenue for contracts entered into or materially modified after January 1, 2011, in accordance with Accounting Standards Update, or ASU, No. 2009-13, Multiple Deliverable Revenue Arrangements. This update amends the guidance on accounting for arrangements with multiple deliverables to require that each deliverable be evaluated to determine whether it qualifies as a separate unit of accounting.  This determination is generally based on whether the deliverable has stand-alone value to the customer.  This update also establishes a selling price hierarchy for determining how to allocate arrangement consideration to identified units of accounting.  The selling price used for each unit of accounting will be based on vendor-specific objective evidence, or VSOE, if available, third-party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third-party evidence is available.  We may be required to exercise considerable judgment in determining whether a deliverable is a separate unit of accounting and the estimated selling price of identified units of accounting for new or modified agreements.
	We account for our Arrangement with Takeda under ASC 605-25 and currently, are operating in the commercialization period as defined in the Arrangement.  Before the recall, we were performing commercialization services such as promotions and marketing as well as development work related to OMONTYS post approval.  In return for these services, we receive a 50/50 share of operating profit from the sale and distribution of OMONTYS (as described below), certain milestone payments and contingent payments due under the Arrangement. We also continue to receive reimbursement of costs for commercial and development costs as described in the Arrangement. Prior to approval of OMONTYS, our primary source of revenue consisted of milestone payments and Takeda’s reimbursement of commercialization and development costs.
	In addition to the profit sharing and reimbursement of the costs described above, the Arrangement provided us the potential to earn substantive at risk milestone payments upon achievement of contractual criteria (see Note 3 of Notes to Financial Statements). However, timing and amounts of these milestones are extremely uncertain due to the recall.
	During the commercialization period, our obligations include ongoing regulatory work to obtain and maintain FDA approval and commercialization efforts related to our product launch and promotion and marketing of OMONTYS.
	For each source of collaboration revenue, we apply the following revenue recognition model:
	•	Expense reimbursement revenue. Revenues related to reimbursements by Takeda of third-party development expenses (70/30 split per the Arrangement) and commercialization expenses (shared 50/50 according to the Arrangement) are recognized as revenue in the period the related costs are incurred.  Revenues related to reimbursement of costs of full-time equivalents, or FTEs, engaged in development related activities such as post-marketing studies, are recognized as revenue in the period the related costs are incurred. Such reimbursement is based on contractually negotiated reimbursement rates for each FTE as specified in the Arrangement.  Subsequent to the launch of OMONTYS and recognition of product revenue by Takeda, reimbursement of commercialization expenses and development costs (both FTE and out of pocket costs) associated with post-marketing development activities, is incorporated into the profit equalization revenue as required under the Arrangement in order to effect the 50/50 profit split, as described below.  As part of the Amendment with Takeda, both Parties agreed that they will no longer share expenses related to third-party development (70/30 split) and commercialization (50/50 split) as of April 1, 2013. Except for certain transition services that we performed in April 2013 for full reimbursement of $0.5 million, any expenses incurred by either us or Takeda after April 1, 2013 shall be the responsibility of the respective party and neither us or Takeda has the obligation to share expenses with each other.
	•	Profit equalization revenue/loss. Subsequent to the launch of OMONTYS and prior to the Amendment, as to the recognition of product revenue by Takeda, Takeda allocates the quarterly profit equalization revenue/loss to us in order to effect the 50/50 profit/loss split from the sale of OMONTYS, as called for by the Arrangement.  Profit equalization revenue/loss is calculated as the amount required so that the profit or loss realized by both us and Takeda on the product equates to 50% of the total product profit or loss.  Total product profit or loss on OMONTYS is calculated on a quarterly basis as gross product sales recorded by Takeda less the following deductions also recorded by Takeda: rebates and discounts, cost of goods, and other gross-to-net adjustments incurred by Takeda; royalty expenses incurred by us, commercialization expenses (FTE related and out of pocket costs) incurred by both Takeda and us, and certain development costs associated with post-marketing development activities (FTE related and out of pocket costs) incurred by both Takeda and us.  Profit equalization revenue is recognized as revenue in the period product revenue is recognized by Takeda.  As a result of the voluntary recall of OMONTYS in February 2013, all marketing activities were suspended. As part of the Amendment with Takeda, the profit equalization revenue for the three months ended March 31, 2013 will be the final profit equalization payment under the Arrangement. Upon signing the Amendment with Takeda, the economics of the collaboration changed from a profit sharing arrangement to a milestone and royalty-based compensation structure to us, effective April 1, 2013.
	•	Milestone revenue. We account for milestones under ASU No. 2010-17, Milestone Method of Revenue Recognition. Under the milestone method, contingent consideration received from the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved, which we believe is more consistent with the substance of our performance under the collaboration. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the entity. A milestone is substantive if the consideration earned from the achievement of the milestone is consistent with our performance required to achieve the milestone or the increase in value to the collaboration resulting from our performance, relates solely to our past performance, and is reasonable relative to all of the other deliverables and payments within the collaboration. Although we are eligible to receive future milestones from Takeda, timing and amounts of future milestone payments, if any are extremely uncertain due to the recall.
	Below is a summary of the components of our collaboration revenue for the years ended December 31, 2013, 2012, and 2011 (in thousands):
		Year ended December 31,
		2013				2012			2011
	Profit equalization revenue	$	5			$	26,544		$	—
	Milestone payments	—				60,250			10,000
	Revenue previously deferred related to API	—				936			—
	Revenue recognized under CAPM	—				—			26,606
	Net expense reimbursement after CAPM	1,364				6,628			11,097
	Total collaboration revenue	$	1,369			$	94,358		$	47,703
	License and Royalty Revenue
	Royalties are recognized as earned in accordance with contract terms, when third party results are reported and collectability is reasonably assured.  Royalties received under agreements that were acquired by us in the 2001 spin out from GlaxoSmithKline or Glaxo are recorded net of the 50% that we are required to remit to Glaxo.
	If Takeda decides to reintroduce OMONTYS, which is highly uncertain, we are eligible to receive potential milestones and royalties. The royalties are tiered in the range of 13% to 17% with respect to net sales in the U.S. and in the range of 13% to 24% depending on the level of net sales by Takeda worldwide outside of the U.S.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	For financial instruments consisting of cash and cash equivalents, receivable from Takeda, advance from Takeda, accounts payable, deposit from Takeda and accrued liabilities included in our financial statements, the carrying amounts are reasonable estimates of fair value due to their short maturities. Estimated fair values for short-term and long-term investments are based on quoted market prices for the same or similar instruments. Based on borrowing rates currently available to us for loans with similar terms, the carrying value of lease obligations approximates fair value.
Inventory	'
	Inventory
	We value our inventories at the lower of cost or net realizable value which is contractually determined in our collaboration with Takeda to be our cost plus a markup.  We determine the cost of inventory using the specific identification method.  We record API as inventory when the title transfers to us from the CMO, until the point of acceptance by Takeda. We initiate orders for API with our CMOs based on forecasts from Takeda. To date all orders have generally commenced once there was a contractual commitment for the API from Takeda.
	We analyze our inventory levels quarterly and write down inventory that has become obsolete or has a cost basis in excess of its expected net realizable value, as well as any inventory quantities in excess of expected requirements.  Any expired inventory is disposed of and the related costs are recognized as expense. The voluntary recall of OMONTYS in February 2013 impacted the recoverability of our inventories based on assumptions about expected demand and net realizable value. In the December 31, 2012 balance sheet, given the significant uncertainty of demand following the recall, we had written down our API inventory and prepayments made to our CMOs to the net realizable value of zero. We also established an accrual for estimated losses on firm inventory purchase commitments by applying the same lower of cost or market approach that is used to value inventory. As of March 31, 2013 this accrued commitment was $32.9 million. However, in the second quarter of 2013, we were able to settle these obligations for $11.0 million resulting in a favorable adjustment to our operating results of $21.9 million in the quarter ended June 30, 2013. As of December 31, 2013, there was no remaining manufacturing obligations or accrued balance.
	We expense costs relating to the production of API as research and development or R&D expense in the period incurred until we receive FDA approval for a new product or product configuration and began to capitalize the subsequent inventory costs relating to that product or product configuration. Prior to approval of OMONTYS for commercial sale in March 2012 by the FDA, we had expensed all costs associated with the production of API as R&D expense. Subsequent to receiving FDA approval of OMONTYS, we commenced capitalization of third party costs which are incurred to manufacture the API used in the production of OMONTYS.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are calculated using the straight-line method over the estimated useful lives of the assets, generally three to five years. Assets under capital lease and leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the related lease. Maintenance and repairs are charged to operations as incurred. All equipment was determined to be held for sale in May 2013 and accordingly no further depreciation was recorded after that determination. Equipment categorized as held for sale on the balance sheet during the year and subsequently sold had a net book value of $0.5 million. All equipment other than computers retained for data storage was sold as of June 30, 2013 and the carrying value of equipment was reduced to zero upon completion of the sale.
Valuation of Long-Lived Assets	'
	Valuation of Long-Lived Assets, Prepaids and Other Assets
	We assess the impairment of long-lived assets when events or changes in circumstances indicate that the carrying value of the assets or the asset grouping may not be recoverable. Factors that we consider in deciding when to perform an impairment review include significant negative industry or economic trends, and significant changes or planned changes in our use of the assets. We measure the recoverability of assets that will continue to be used in our operations by comparing the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping's carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired. The impairment is measured by comparing the difference between the asset grouping's carrying value and its fair value. Fair value is the price that would be received from selling an asset in an orderly transaction between market participants at the measurement date. Long-lived assets such as intangible assets and property, plant and equipment are considered non-financial assets, and are recorded at fair value only when an impairment charge is recognized. The recall of OMONTYS was considered to be an impairment indicator for certain assets. We evaluated the recoverability of our assets and determined that certain assets were impaired. We recorded impairment charges for the year ended December 31, 2013 of $4.4 million. These charges are reflected in the statement of operations under the caption "Impairment (gain on disposal) of prepaid expenses, fixed assets, and intangible assets.
Net Loss Per Common Share	'
	Net Loss Per Common Share
	Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period.  Stock options, warrants, unvested restricted stock units or RSUs, and common stock issuable pursuant to the 2006 Employee Stock Purchase Plan were not included in the diluted net loss per common share calculation for the periods presented because the inclusion of such shares would have had an antidilutive effect.
	The computations for basic and diluted net loss per share are as follows (in thousands):
		Year ended December 31,
		2013				2012			2011
	Numerator:
	Net loss	$	(14,424	)		$	(93,412	)	$	(61,367	)
	Denominator:
	Weighted-average number of common shares used in computing basic and diluted net loss per common share	37,448				36,342			33,288
	Basic and diluted net loss per common share	$	(0.39	)		$	(2.57	)	$	(1.84	)
	The following shares were excluded from the computation of diluted net loss per common share for the periods presented because including them would have an antidilutive effect (in thousands):
		Year ended December 31,
		2013			2012			2011
	Options to purchase common stock	1,840			4,858			4,262
	Common stock issuable pursuant to the 2006 Employee Stock Purchase Plan	—			40			41
	Restricted stock units	—			297			362
	Warrant to purchase common stock	424			424			426
Stock-Based Compensation	'
	Stock-Based Compensation
	We account for equity instruments issued to employees and directors under the authoritative guidance for share-based payments.
	The equity instruments we most typically grant are stock options and RSUs. Stock options are valued using the Black-Scholes valuation model while the fair value of RSUs is equivalent to the market value of the equivalent number of shares of common stock on the date of grant. The measurement of stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest or do not vest as a result of employee terminations prior to vesting.
	We have issued stock options to non-employees. We account for equity instruments issued to non-employees in accordance with the authoritative guidance for equity-based payments to non-employees, using a fair value approach.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of computations of basic and diluted net loss per share	'
		Year ended December 31,
		2013				2012			2011
	Numerator:
	Net loss	$	(14,424	)		$	(93,412	)	$	(61,367	)
	Denominator:
	Weighted-average number of common shares used in computing basic and diluted net loss per common share	37,448				36,342			33,288
	Basic and diluted net loss per common share	$	(0.39	)		$	(2.57	)	$	(1.84	)
Schedule of antidilutive shares excluded from the computation of diluted net loss per common share	'
	The following shares were excluded from the computation of diluted net loss per common share for the periods presented because including them would have an antidilutive effect (in thousands):
		Year ended December 31,
		2013			2012			2011
	Options to purchase common stock	1,840			4,858			4,262
	Common stock issuable pursuant to the 2006 Employee Stock Purchase Plan	—			40			41
	Restricted stock units	—			297			362
	Warrant to purchase common stock	424			424			426

Balance_Sheet_Components_Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Property and equipment	'
	Property and equipment consist of the following (in thousands):
		December 31,
		2013		2012
	Leasehold improvements	$	—	$	2,501
	Equipment	—		9,794
	Software	—		3,064
	Construction in progress	—		9
		—		15,368
	Less: Accumulated depreciation and amortization	—		(12,387		)
		$	—	$	2,981
Accrued liabilities	'
	Accrued liabilities consist of the following (in thousands):
		December 31,
		2013		2012
	Accrued potential losses related to firm purchase commitments	$	—	$	34,599
	Restructuring accrual	315		—
	Compensation-related expenses	—		12,837
	SG&A related costs	266		3,633
	R&D related costs	—		830
	Other	—		623
		$	581	$	52,522

Investments_Tables

Investments (Tables)	12 Months Ended
	Dec. 31, 2013
Available-for-sale Securities [Abstract]	'
Summary of available-for-sale marketable securities	'
		As of December 31, 2012
		Cost		Gross		Gross			Fair Value
				Unrealized		Unrealized
				Gains		Losses
	Short-term investments:
	Certificates of deposit	$	1,300	$	—	$	—		$	1,300
	Corporate debt securities	8,416		1		—			8,417
	Total short-term investments	$	9,716	$	1	$	—		$	9,717
	Long-term investments:
	Corporate debt securities	$	2,326	$	—	$	(3	)	$	2,323
	Total long-term investments	$	2,326	$	—	$	(3	)	$	2,323

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Schedule of investments measured at fair value on a recurring basis classified by the fair value measurements and disclosures valuation hierarchy	'
		As of December 31, 2012
				Fair Value Measurements Using
		Total		Level 1		Level 2		Level 3
	Money market funds	$	45,999	$	45,999	$	—	$	—
	Short-term investments:
	Certificates of deposit	$	1,300	$	—	$	1,300	$	—
	Corporate debt securities	8,417		—		8,417		—
	Total short-term investments	$	9,717	$	—	$	9,717	$	—
	Long term investments:
	Corporate debt securities	$	2,323	$	—	$	2,323	$	—
	Total long-term investments	$	2,323	$	—	$	2,323	$	—

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of future minimum payments under noncancelable lease obligations	'
	Future minimum payments under non-cancelable lease obligations as of December 31, 2013 are as follows (in thousands):
	2014	23
	Total minimum lease payments	$	23

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of stock-based compensation recorded in the condensed statements of comprehensive loss	'
	Stock-based compensation was recorded in the statements of operations as follows (in thousands):
		Year ended December 31,
		2013				2012				2011
	Research and development	$	878			$	4,324			$	4,632
	Selling, general and administrative	3,564				6,887				5,393
	Total	$	4,442			$	11,211			$	10,025
Schedule of stock options and restricted stock units to employees and directors	'
	We granted the following stock options and RSUs to employees and directors as follows:
		Year ended December 31,
		2013							2012					2011
		Number of			Weighted-				Number of			Weighted-		Number of	Weighted-
		Shares			Average Grant				Shares			Average Grant		Shares	Average Grant
					Date Fair Value							Date Fair Value			Date Fair Value
					Per Share							Per Share			Per Share
	Stock options	888,778			$	15.79			2,142,286			$	8.26	1,110,924	$	4.41
	Restricted stock units	393,195			$	16.36			184,963			$	7.99	220,856	$	6.96
	The following tables summarize information about stock option and RSU activity for the year ended December 31, 2013:
		Number of			Weighted-				Weighted-		Aggregate
		Shares			Average Exercise Price				Average		Intrinsic Value
					(Per Share)(1)				Remaining		(in thousands)(2)
									Contractual
									Term
									(in years)
	Stock Options:
	Balances at December 31, 2012	4,857,536			$	13.49
	Granted	888,778			18.83
	Exercised (3)	(30,918	)		8.77
	Forfeited	(2,889,025	)		13.35
	Cancelled	(986,514	)		13.74
	Balances at December 31, 2013	1,839,857			$	16.24			3.56		$	—
	Options exercisable at	1,551,929			$	17.06			2.76		$	—
	31-Dec-13
	Options vested and expected to vest at December 31, 2013	1,834,691			$	16.24			3.55		$	—
		Number of			Weighted-				Weighted-			Aggregate
		Shares			Average Grant Date Fair Value				Average			Intrinsic Value
					(Per Share)(1)				Remaining			(in thousands)(2)
									Contractual
									Term
									(in years)
	Restricted Stock Units:
	Balances at December 31, 2012	296,723			$	7.54
	Granted (time-based)	393,195			16.36
	Vested	(89,460	)		7.58
	Forfeited	(600,458	)		—
	Balances at December 31, 2013	—			$	—			—			$	—
	_______________________________________________________________________________
	-1	The weighted average price per share is determined using exercise price per share for stock options and fair value per share on grant date for restricted stock units.
	-2	The aggregate intrinsic value is calculated as:
	•	For options: the difference between the exercise price of the option and the fair value of our common stock for in-the-money options at December 31, 2013.
	•	For restricted stock units: the difference between the grant date fair value of the unit and the fair value of our common stock for in-the-money units at December 31, 2013.
	-3	The total intrinsic value of stock options exercised was $0.3 million, $10.6 million, and $0.3 million during the years ended December 31, 2013, 2012, and 2011, respectively, and was determined at the date of each exercise.
Schedule of fair value of employee and direcotr stock options estimated using weighted-average assumptions	'
	The fair value of employee and director stock options was estimated using the following weighted-average assumptions for the years ended December 31, 2013, 2012, and 2011:
		Year ended December 31,
		2013			2012			2011
	Expected volatility	120	%		81	%		80	%
	Risk-free interest rate	0.77	%		0.89	%		1.86	%
	Dividend yield	0	%		0	%		0	%
	Expected term (in years)	5.4			5.5			5.6
Schedule of fair value of employee stock purchase rights	'
	The fair value of employee stock purchase rights were estimated using the following assumptions for the years ended December 31, 2013, 2012 and 2011:
		Year ended December 31,
		2013		2012		2011
	Expected volatility	—%		50%-106%		50%-157%
	Risk-free interest rate	—%		0.04%-0.57%		0.04%-1.00%
	Dividend yield	—%		—%		—%
	Expected term (in months)	—		24-Jun		24-Jun
Schedule of stock options outstanding and exercisable by exercise price	'
	The stock options outstanding and exercisable by exercise price at December 31, 2013 are as follows:
		Stock Options Outstanding							Stock Options Exercisable
	Range of Exercise Prices	Number of			Weighted-		Weighted-		Number of			Weighted-
		Shares			Average		Average		Shares			Average
					Remaining		Exercise					Exercise
					Contractual		Price Per Share					Price Per Share
					Life in Years
	$0.80 - 10.99	728,358			8.21		$7.31		542,799			$7.32
	$11.00 - 20.22	417,558			8.12		$16.87		333,921			$16.23
	$20.23 - 32.89	583,246			6.81		$23.56		564,509			$23.59
	$32.90 - 33.97	110,700			3.78		$33.97		110,700			$33.97
	$0.80 - 33.97	1,839,862			7.73		$16.23		1,551,929			$17.06

Restructuring_Charge_Tables

Restructuring Charge (Tables)	12 Months Ended
	Dec. 31, 2012
Restructuring and Related Activities [Abstract]	'
Summarizes the accrual balance and utilization by type for the restructuring	'
	The following table summarizes the accrual balance and utilization by type for the 2013 restructuring (in thousands):
		Facilities			Employee			Total
		Related			Related
	Balance as of December 31, 2012	$	—		$	—		$	—
	Restructuring charges accrued	2,500			14,766			17,266
	Adjustments	—			(1,200		)	(1,200		)
	Cash payments	(2,500		)	(13,251		)	(15,751		)
	Balance at December 31, 2013	$	—		$	315		$	315

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of the components of the provision for income taxes	'
	The components of the provision for income taxes are as follows (in thousands):
		Year ended December 31,
		2013				2012				2011
	Provision (benefit) for income taxes:
	Current provision (benefit) for income taxes:
	Federal	$	(26	)		$	(27	)		$	—
	State	(2,132		)		1				1
	Total current provision (benefit) for income taxes	(2,158		)		(26		)		1
	Deferred tax benefit:
	Federal	—				—				—
	State	—				—				—
	Total deferred tax benefit	—				—				—
	Provision (benefit) for income taxes	$	(2,158	)		$	(26	)		$	1
Scedule of a reconciliation of the federal statutory income tax rate to the effective income tax rate	'
	A reconciliation of the federal statutory income tax rate to our effective income tax rate is as follows:
		Year ended December 31,
		2013			2012			2011
	Federal statutory income tax rate	(35.00	)%		(35.00	)%		(35.00	)%
	State income taxes, net of federal benefit	(12.85	)		—			—
	Stock-based compensation expense	9.76			3.04			4.15
	Change in valuation allowance	(7.89	)		32.52			(56.26	)
	Change in federal rates and prior year true ups	32.81			(0.64	)		0.7
	Permanent differences	0.32			0.08			0.08
	Tax credits	—			—			2.66
	Changes in tax reserves	(0.15	)		(0.03	)		—
	Impairment of tax attributes due to ownership change	—			—			83.67
	Provision (benefit) for income taxes	(13.00	)%		(0.03	)%		0	%
Schedule of deferred tax assets	'
	Deferred tax assets consist of the following (in thousands):
		December 31,
		2013				2012
	Net operating loss carryforwards	$	138,165			$	113,956
	Federal and State credit carryforwards	4,263				4,249
	Depreciation and amortization	8,174				11,866
	Capitalized start-up costs	1,037				1,185
	Accrued liabilities and allowances	6,694				35,955
	Gross deferred tax assets	158,333				167,211
	Deferred tax liability	—				—
	Net deferred tax asset	158,333				167,211
	Less: Valuation allowance	(158,333		)		(159,971		)
	Net deferred tax assets	$	—			$	7,240
Schedule of a reconciliation of the unrecognized tax benefits	'
	A reconciliation of the unrecognized tax benefits for the years ended December 31, 2013, 2012, and 2011, is as follows (in thousands):
		December 31,
		2013				2012				2011
	Balance at beginning of year	$	73,017			$	70,613			$	13,100
	Additions for current year tax positions	—				—				59,419
	Additions for prior year tax positions	—				2,437				—
	Reductions for statute of limitations	(1,825		)		(27		)		—
	Reductions for prior year tax positions	(338		)		(6		)		(1,906		)
	Balance at end of year	$	70,854			$	73,017			$	70,613

Quarterly_Financial_Data_Table

Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of quarterly financial information	'
	The following tables summarize the unaudited quarterly financial data for the last two fiscal years (in thousands, except per share data):
		2013 Quarter Ended
					March 31,
	Unaudited quarterly financial data	As reported			Revisions (a)			As Revised (a)			June 30,			September 30,			December 31,
	Collaboration revenue	$	839		$	—		$	839		$	525		$	—		$	—
	Total revenue	844			—			844			525			—			—
	Research and development	9,736			53			9,789			2,235			(166		)	(1		)
	Selling, general and administrative	24,346			318			24,664			528			1,886			451
	Income (loss) from operations	(26,196		)	(371		)	(26,567		)	14,271			(1,692		)	(1,058		)
	Net income (loss)	(26,674		)	(371		)	(27,045		)	15,372			(1,692		)	(1,059		)
	Basic net income (loss) per common share	$	(0.71	)	$	(0.01	)	$	(0.72	)	$	0.41		$	(0.05	)	$	(0.03	)
	Weighted-average number of common shares used in computing basic net income (loss) per common share calculation	37,469			—			37,469			37,490			37,490			37,490
	Diluted net income (loss) per common share	$	(0.71	)	$	(0.01	)	$	(0.72	)	$	0.41		$	(0.05	)	$	(0.03	)
	Weighted-average number of common shares used in computing diluted net income (loss) per common share calculation	37,469			—			37,469			37,495			37,490			37,490
	Unaudited balance sheet data							March 31, 2013			June 30, 2013			September 30, 2013
	Additional paid in capital (revised) (Note a)							$	555,947		$	554,509		$	555,007
	Accumulated deficit (revised) (Note a)							$	(570,387	)	$	(554,219	)	$	(555,911	)
	(a) During the fourth quarter of 2013, an error was identified in the unaudited financial statements for the first quarter of 2013 related to the accounting for our former employee stock purchase plan (ESPP). We incorrectly accounted for the termination and cancellation of awards under the ESPP plan related to the significant reduction of our headcount during that period. We evaluated the materiality of the error from a quantitative and qualitative perspective, and concluded that the error was not material to the unaudited financial statements for the three-month period ended March 31, 2013, the six-month period ended June 30, 2013, or the nine-month period ended September 30, 2013. Although the error was not material, we have elected to correct the error by recording an adjustment of $371,000 in the first quarter of 2013 to increase the expense in that period for cancellations of awards, net of adjustments to reverse the unvested compensation expense which had previously been recorded for awards which were forfeited. Of this total adjustment, $53,000 related to research and development expenses and $318,000 related to selling, general and administrative expenses. The correction also increased the previously reported adjustment to reconcile net (loss) income to net cash used in operating activities related to share-based compensation expense in the unaudited statements of cash flows by $371,000 for the three-month period ended March 31, 2013, the six-month period ended June 30, 2013, and the nine-month period ended September 30, 2013. The total of cash used in operating activities in these periods was not affected by the correction.
		2012 Quarter Ended
		March 31,			June 30,			September 30,			December 31,
	Collaboration revenue	$	63,205		$	2,754		$	13,603		$	14,796
	Total revenue	63,209			2,755			13,607			14,799
	Loss from operations	31,520			(31,381		)	(23,990		)	(68,188		)
	Net loss	31,453			(31,956		)	(24,638		)	(68,271		)
	Basic net income (loss) per common share	$	0.88		$	(0.89	)	$	(0.68	)	$	(1.85	)
	Weighted-average number of common shares used in computing basic net income (loss) per common share calculation	35,772			36,075			36,350			36,846
	Diluted net income (loss) per common share	$	0.87		$	(0.89	)	$	(0.68	)	(1.85		)
	Weighted-average number of common shares used in computing diluted net income (loss) per common share calculation	36,338			36,075			36,350			36,846

The_Company_Details

The Company (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Liabilities, Current	$8,871	$99,075	'	'
Accumulated deficit	-558,137	-543,713	'	'
Cash and cash equivalents	$5,597	$68,265	$54,339	$63,499

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Concentration of Risk) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Concentration Risk [Line Items]	'	'
Accumulated deficit	$558,137	$543,713
Accounts receivable balance with Takeda	0	18,365
Takeda Pharmaceutical Company Limited [Member]	'	'
Concentration Risk [Line Items]	'	'
Accounts receivable balance with Takeda	$0	$18,400

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Revenue Recognition) (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Collaboration Revenue

'

'

'

'

'

'

'

'

'

'

'

'

Property and equipment, net

$0

'

'

'

$2,981,000

'

'

'

'

$0

$2,981,000

'

Asset Impairment Charges

'

'

'

'

'

'

'

'

4,400,000

5,118,000

'

'

Accrued Losses Purchase Commitments

0

[1]

'

'

32,900,000

34,599,000

[1]

'

'

'

'

0

[1]

34,599,000

[1]

'

Components of collaboration revenue

'

'

'

'

'

'

'

'

'

'

'

'

Total collaboration revenue

0

0

525,000

839,000

14,796,000

13,603,000

2,754,000

63,205,000

'

1,364,000

94,358,000

47,703,000

License and Royalty Revenue

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Commitment, Payment

'

11,000,000

'

1,700,000

'

'

'

'

'

'

'

'

Purchase Commitment Reserve, Accrual Adjustment

'

21,900,000

'

'

'

'

'

'

'

'

'

'

Takeda Pharmaceutical Company Limited [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Collaboration Revenue

'

'

'

'

'

'

'

'

'

'

'

'

Reimbursement Revenue

'

'

'

'

'

'

'

'

'

500,000

'

'

Takeda Pharmaceutical Company Limited [Member] | Arrangement - Product [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Components of collaboration revenue

'

'

'

'

'

'

'

'

'

'

'

'

Profit equalization revenue

'

'

'

'

'

'

'

'

'

5,000

26,544,000

0

Milestone payments

'

'

'

'

'

'

'

'

'

0

60,250,000

10,000,000

Revenue previously deferred related to API

'

'

'

'

'

'

'

'

'

0

936,000

0

Revenue recognized under CAPM

'

'

'

'

'

'

'

'

'

0

0

26,606,000

Net expense reimbursement after CAPM

'

'

'

'

'

'

'

'

'

1,364,000

6,628,000

11,097,000

Total collaboration revenue

'

'

'

'

'

'

'

'

'

$1,369,000

$94,358,000

$47,703,000

License and Royalty Revenue

'

'

'

'

'

'

'

'

'

'

'

'

Development expense, percentage of reimbursement

'

'

'

'

'

'

'

'

'

70.00%

'

'

Commercialization expense, percentage of reimbursement

'

'

'

'

'

'

'

'

'

50.00%

'

'

Profit Equalization percentage as outlined in collaboration agreement

'

'

'

'

'

'

'

'

50.00%

'

'

'

Affymax [Member] | Arrangement - Product [Member]

'

'

'

'

'

'

'

'

'

'

'

'

License and Royalty Revenue

'

'

'

'

'

'

'

'

'

'

'

'

Development expense, percentage of reimbursement

'

'

'

'

'

'

'

'

'

'

30.00%

'

Commercialization expense, percentage of reimbursement

'

'

'

'

'

'

'

'

'

'

50.00%

'

Profit Equalization percentage as outlined in collaboration agreement

'

'

'

'

'

'

'

'

'

50.00%

'

'

Glaxo Smith Kline [Member]

'

'

'

'

'

'

'

'

'

'

'

'

License and Royalty Revenue

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of royalties received to royalties required to be remitted to Glaxo

'

'

'

'

'

'

'

'

'

'

50.00%

'

Minimum [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Collaboration Revenue

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment, Useful Life

'

'

'

'

'

'

'

'

'3 years

'

'

'

Minimum [Member] | Foreign [Member] | Takeda Pharmaceutical Company Limited [Member]

'

'

'

'

'

'

'

'

'

'

'

'

License and Royalty Revenue

'

'

'

'

'

'

'

'

'

'

'

'

Net Sales Royalties, Tiered Percentage

'

'

'

'

'

'

'

'

13.00%

'

'

'

Maximum [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Collaboration Revenue

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment, Useful Life

'

'

'

'

'

'

'

'

'5 years

'

'

'

Maximum [Member] | Foreign [Member] | Takeda Pharmaceutical Company Limited [Member]

'

'

'

'

'

'

'

'

'

'

'

'

License and Royalty Revenue

'

'

'

'

'

'

'

'

'

'

'

'

Net Sales Royalties, Tiered Percentage

'

'

'

'

'

'

'

'

24.00%

'

'

'

[1]

{F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjY1NGY0YjEwZDNhNTQ0NzJhYzQ2NmIxODFkYjEyZWYwfFRleHRTZWxlY3Rpb246ODc2MzJCQ0FBQUE2M0ZFNDM4OTlCNDZDNDYzNTFCQ0QM}

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Inventory) (Details) (USD $)	Dec. 31, 2013		Mar. 31, 2013	Dec. 31, 2012		Sep. 30, 2013	Dec. 31, 2012
						Commercial API Supply Agreement [Member]	Commercial API Supply Agreement [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]	'		'	'		'	'
Inventory, Net	'		'	'		$0	'
Advances on inventory purchases	'		'	17,800,000		'	'
Inventory write-down	'		'	'		10,400,000	'
Accrued Losses Purchase Commitments	$0	[1]	$32,900,000	$34,599,000	[1]	'	$10,400,000
[1]	{F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjY1NGY0YjEwZDNhNTQ0NzJhYzQ2NmIxODFkYjEyZWYwfFRleHRTZWxlY3Rpb246ODc2MzJCQ0FBQUE2M0ZFNDM4OTlCNDZDNDYzNTFCQ0QM}

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Property and Equipment) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
In Thousands, unless otherwise specified			Minimum [Member]	Maximum [Member]	Assets Sold [Member]
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'3 years	'5 years	'
Property and equipment, net	$0	$2,981	'	'	$500

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Net Loss Per Common Share) (Details) (USD $)	3 Months Ended				12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net Income (Loss) Per Common Share	'	'	'	'	'	'	'
Net loss	'	'	'	'	($14,424)	($93,412)	($61,367)
Weighted-average number of common shares used in computing basic and diluted net loss per common share	36,846	36,350	36,075	35,772	37,448	36,342	33,288
Basic and diluted net loss per common share	'	'	'	'	($0.39)	($2.57)	($1.84)
Options to purchase common stock [Member]	'	'	'	'	'	'	'
Antidilutive shares excluded from the computation of diluted net income (loss) per common share	'	'	'	'	'	'	'
Antidilutive shares excluded from the computation of diluted net income (loss) per common share	'	'	'	'	1,840	4,858	4,262
Common stock issuable pursuant to the 2006 Employee Stock Purchase Plan [Member]	'	'	'	'	'	'	'
Antidilutive shares excluded from the computation of diluted net income (loss) per common share	'	'	'	'	'	'	'
Antidilutive shares excluded from the computation of diluted net income (loss) per common share	'	'	'	'	0	40	41
Restricted stock units [Member]	'	'	'	'	'	'	'
Antidilutive shares excluded from the computation of diluted net income (loss) per common share	'	'	'	'	'	'	'
Antidilutive shares excluded from the computation of diluted net income (loss) per common share	'	'	'	'	0	297	362
Warrant to purchase common stock [Member]	'	'	'	'	'	'	'
Antidilutive shares excluded from the computation of diluted net income (loss) per common share	'	'	'	'	'	'	'
Antidilutive shares excluded from the computation of diluted net income (loss) per common share	'	'	'	'	424	424	426

Development_and_Commercializat1

Development and Commercialization Agreements with Takeda (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Mar. 31, 2013

Sep. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2013

Mar. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Mar. 31, 2012

Dec. 31, 2012

Nov. 30, 2011

Nov. 30, 2011

Nov. 30, 2011

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Affymax [Member]

Affymax [Member]

Affymax [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Sale Based Milestone Ten Million [Member]

Sale Based Milestone Twenty Million [Member]

Sale Based Milestone Thirty Million [Member]

Sale Based Milestone Fourty Million [Member]

Sale Based Milestone Fifty Million [Member]

Sales Based Milestone Point Five Billion [Member]

Sales Based Milestone One Billion [Member]

Sales Based Milestone One Point Five Billion [Member]

Sales Based Milestone Two Billion [Member]

Sales Based Milestone Three Billion [Member]

Commercial API Supply Agreement [Member]

Commercial API Supply Agreement [Member]

Commercial API Supply Agreement [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Milestone Payment Based on Sales, First Commercial Sale After Reintroduction of O.M.O.N.T.Y.S [Member]

Milestone Payment Based On Sales Foreign Sales Based Milestone [Member]

Milestone payment based on sales, aggregate net sales reached [Member]

Milestone Payment Based on Sales, U.S Sales-based Milestone One [Member]

Milestone Payment Based on Sales, U.S Sales-based Milestone Two [Member]

Commercial API Supply Agreement [Member]

Product Development and Commercialization [Member]

Product Development and Commercialization - February 2012 Agreement [Member]

Baxter Prefilled Syringes Agreement [Member]

Milestone payment upon FDA approval [Member]

Commercial API Supply Agreement [Member]

Commercial API Supply Agreement [Member]

Product Development and Commercialization [Member]

Product Development and Commercialization [Member]

Product Development and Commercialization [Member]

Product Development and Commercialization [Member]

Product Development and Commercialization [Member]

Product Development and Commercialization [Member]

Product Development and Commercialization - February 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - February 2012 Agreement [Member]

Arrangement - Co-promotion [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Commercial API Supply Agreement [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Cost sharing agreements [Member]

Launch Allowance - Cost sharing agreements [Member]

Milestone payment based on regulatory, commercial or clinical development [Member]

U.S. [Member]

Milestone payment upon acceptance of MAA filing for OMONTYS by EMA [Member]

Milestone payment upon FDA approval [Member]

Launch Allowance - Cost sharing agreements [Member]

Commercial API Supply Agreement [Member]

Milestone payment based on regulatory, commercial or clinical development [Member]

Milestone payment based on regulatory, commercial or clinical development [Member]

Milestone payment based on regulatory, commercial or clinical development [Member]

Milestone payment based on regulatory, commercial or clinical development [Member]

Milestone payments resulting from settlement and license agreement with Janssen [Member]

Milestone payment resulting from progress on the commercial launch of OMONTYS [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

U.S. [Member]

U.S. [Member]

U.S. [Member]

Japan [Member]

U.S. [Member]

U.S. [Member]

U.S. [Member]

U.S. [Member]

U.S. [Member]

European Union [Member]

Milestone payment based on sales, aggregate net sales reached [Member]

Milestone payment based on sales, aggregate net sales reached [Member]

Milestone payment based on sales, aggregate net sales reached [Member]

Milestone payment based on sales, aggregate net sales reached [Member]

Milestone payment based on sales, aggregate net sales reached [Member]

Milestone payment based on sales, aggregate net sales reached [Member]

Milestone payment based on sales, aggregate net sales reached [Member]

Milestone payment based on sales, aggregate net sales reached [Member]

Milestone payment based on sales, aggregate net sales reached [Member]

Milestone payment based on sales, aggregate net sales reached [Member]

Development and Commercialization agreements with Takeda

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaboration revenue recognized

$0

$0

$525,000

$839,000

$14,796,000

$13,603,000

$2,754,000

$63,205,000

$1,364,000

$94,358,000

$47,703,000

'

'

'

'

'

'

'

'

'

$1,369,000

$94,358,000

$47,703,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reimbursement Revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued liabilities

'

'

'

'

'

'

'

'

-28,335,000

3,849,000

2,405,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase commitment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of Long-Lived Assets Held-for-use

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventory recall expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,100,000

'

'

'

'

'

'

Profit Equalization Losses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

Net receivable balance from Takeda

0

'

'

'

18,365,000

'

'

'

0

18,365,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

18,400,000

'

'

'

'

'

'

'

'

Cost sharing percentage of third party development expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

70.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of third-party commercialization expenses to be borne

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate amount receivable if clinical development and regulatory milestones are successfully achieved

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33,000,000

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

500,000,000

1,000,000,000

1,500,000,000

2,000,000,000

3,000,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Commitment, Payment

'

11,000,000

'

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Commitment Reserve, Accrual Adjustment

'

21,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential milestone payments not pursued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments received from collaborative agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of net sales deducted from the profit share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of threshold limit of deduction from net sales from the profit share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fixed interest amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Profit equalization revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

26,544,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advance from Takeda

8,189,000

'

'

'

27,715,000

'

'

'

8,189,000

27,715,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,200,000

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestones recognized as revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

60,250,000

10,000,000

'

'

'

'

5,000,000

50,000,000

'

'

'

3,000,000

3,000,000

'

'

'

2,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential Commercial Milestone Payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

150,000,000

180,000,000

10,000,000

10,000,000

Potential Development Milestone Payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Sales Royalties, Tiered Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13.00%

'

17.00%

'

'

'

'

'

Additional reimbursement percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deposit balance

0

'

'

'

559,000

'

'

'

0

559,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventory write-down

'

'

'

'

'

'

'

'

'

'

'

15,900,000

'

'

'

'

'

31,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,400,000

'

'

'

'

'

'

'

'

'

'

'

Accrued Losses Purchase Commitments

0

[1]

'

'

32,900,000

34,599,000

[1]

'

'

'

0

[1]

34,599,000

[1]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,400,000

'

'

'

'

'

'

'

'

'

'

Impairment of inventory and losses on firm purchase commitments

'

'

'

'

'

'

'

'

0

44,957,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaboration Cost Reimbursement

'

'

'

20,300,000

'

'

'

'

43,451,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advances on inventory purchases

'

'

'

'

17,800,000

'

'

'

'

17,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Profit Sharing percentage as outlined in collaboration agreement

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

50.00%

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential estimated obligations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential Sales-Based Milestone

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,300,000

$1,300,000

$6,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

{F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjY1NGY0YjEwZDNhNTQ0NzJhYzQ2NmIxODFkYjEyZWYwfFRleHRTZWxlY3Rpb246ODc2MzJCQ0FBQUE2M0ZFNDM4OTlCNDZDNDYzNTFCQ0QM}

Contractual_Arrangements_Detai

Contractual Arrangements (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2013

Jun. 30, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Purchase Comment PEG [Member]

Purchase Commitment API [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Fixed payments [Member]

Fixed payments [Member]

Fixed payments [Member]

Milestone payment upon FDA regulatory approval of OMONTYS [Member]

Milestone payment upon FDA regulatory approval of OMONTYS in the first major European country [Member]

numberofagreements

Development and Commercialization agreements with Takeda

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Losses Purchase Commitments

'

$32,900,000

'

$0

[1]

$34,599,000

[1]

'

$5,800,000

$28,800,000

'

'

'

'

'

'

'

Purchase Commitment, Payment

11,000,000

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Commitment Reserve, Accrual Adjustment

21,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of fixed payments to be made under the agreement

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

Amount of fixed payments to be made under the agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

Fixed or milestone payments

'

'

'

'

'

'

'

'

'

'

2,000,000

6,000,000

'

2,500,000

'

Research and development

'

'

'

11,857,000

51,738,000

76,308,000

'

'

'

'

'

'

8,000,000

'

'

Amount capitalized relating to first milestone payment

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

'

Asset Impairment Charges

'

'

$4,400,000

$5,118,000

'

'

'

'

$1,900,000

'

'

'

'

'

'

[1]

{F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjY1NGY0YjEwZDNhNTQ0NzJhYzQ2NmIxODFkYjEyZWYwfFRleHRTZWxlY3Rpb246ODc2MzJCQ0FBQUE2M0ZFNDM4OTlCNDZDNDYzNTFCQ0QM}

Balance_Sheet_Components_Prope

Balance Sheet Components (Property and Equipment, Net) (Details) (USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, gross	'	$0	$15,368,000	'
Less: Accumulated depreciation and amortization	'	0	-12,387,000	'
Property and equipment, net	'	0	2,981,000	'
Depreciation and amortization expense	'	722,000	1,987,000	2,182,000
Asset Impairment Charges, Fixed Assets	'	1,900,000	'	'
Proceeds from sale of property and equipment	1,200,000	1,225,000	25,000	41,000
Gain (Loss) on Sale of Property Plant Equipment	700,000	704,000	-30,000	-11,000
Leasehold improvements [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, gross	'	0	2,501,000	'
Equipment [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, gross	'	0	9,794,000	'
Software [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, gross	'	0	3,064,000	'
Construction in progress [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and equipment, gross	'	$0	$9,000	'

Balance_Sheet_Components_Accru

Balance Sheet Components (Accrued Liabilities) (Details) (USD $)	Dec. 31, 2013		Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]	'		'	'
Accrued Losses Purchase Commitments	$0	[1]	$32,900	$34,599	[1]
Restructuring Reserve, Current	315		'	'
Compensation-related expenses	0		'	12,837
SG&A related costs	266	[2]	'	3,633	[2]
R&D related costs	0		'	830
Other	0		'	623
Accrued liabilities	$581		'	$52,522
[1]	{F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjY1NGY0YjEwZDNhNTQ0NzJhYzQ2NmIxODFkYjEyZWYwfFRleHRTZWxlY3Rpb246ODc2MzJCQ0FBQUE2M0ZFNDM4OTlCNDZDNDYzNTFCQ0QM}
[2]	Text selection found with no content.

Investments_Details

Investments (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Available-for-sale marketable securities	'	'
Fair Value	$0	$9,717
Short-term investments [Member]	'	'
Available-for-sale marketable securities	'	'
Cost	'	9,716
Gross Unrealized Gains	'	1
Gross Unrealized Losses	'	0
Fair Value	'	9,717
Short-term investments [Member] | Certificates of deposit [Member]	'	'
Available-for-sale marketable securities	'	'
Cost	'	1,300
Gross Unrealized Gains	'	0
Gross Unrealized Losses	'	0
Fair Value	'	1,300
Short-term investments [Member] | Corporate debt securities [Member]	'	'
Available-for-sale marketable securities	'	'
Cost	'	8,416
Gross Unrealized Gains	'	1
Gross Unrealized Losses	'	0
Fair Value	'	8,417
Long-term investments [Member]	'	'
Available-for-sale marketable securities	'	'
Cost	'	2,326
Gross Unrealized Gains	'	0
Gross Unrealized Losses	'	-3
Fair Value	'	2,323
Long-term investments [Member] | Corporate debt securities [Member]	'	'
Available-for-sale marketable securities	'	'
Cost	'	2,326
Gross Unrealized Gains	'	0
Gross Unrealized Losses	'	-3
Fair Value	'	$2,323

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Short-term investments:	'	'
Short-term investments	$0	$9,717
Long-term Investments:	'	'
Long-term investments	0	2,323
Short-term investments [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	9,717
Short-term investments [Member] | Certificates of deposit [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	1,300
Short-term investments [Member] | Corporate debt securities [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	8,417
Long-term investments [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	2,323
Long-term investments [Member] | Corporate debt securities [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	2,323
Recurring [Member] | Total [Member]	'	'
Fair value measurements	'	'
Money market funds	'	45,999
Recurring [Member] | Total [Member] | Short-term investments [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	9,717
Recurring [Member] | Total [Member] | Short-term investments [Member] | Certificates of deposit [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	1,300
Recurring [Member] | Total [Member] | Short-term investments [Member] | Corporate debt securities [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	8,417
Recurring [Member] | Total [Member] | Long-term investments [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	2,323
Recurring [Member] | Total [Member] | Long-term investments [Member] | Corporate debt securities [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	2,323
Recurring [Member] | Level 1 [Member]	'	'
Fair value measurements	'	'
Money market funds	'	45,999
Recurring [Member] | Level 1 [Member] | Short-term investments [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	0
Recurring [Member] | Level 1 [Member] | Short-term investments [Member] | Certificates of deposit [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	0
Recurring [Member] | Level 1 [Member] | Short-term investments [Member] | Corporate debt securities [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	0
Recurring [Member] | Level 1 [Member] | Long-term investments [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	0
Recurring [Member] | Level 1 [Member] | Long-term investments [Member] | Corporate debt securities [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	0
Recurring [Member] | Level 2 [Member]	'	'
Fair value measurements	'	'
Money market funds	'	0
Recurring [Member] | Level 2 [Member] | Short-term investments [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	9,717
Recurring [Member] | Level 2 [Member] | Short-term investments [Member] | Certificates of deposit [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	1,300
Recurring [Member] | Level 2 [Member] | Short-term investments [Member] | Corporate debt securities [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	8,417
Recurring [Member] | Level 2 [Member] | Long-term investments [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	2,323
Recurring [Member] | Level 2 [Member] | Long-term investments [Member] | Corporate debt securities [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	2,323
Recurring [Member] | Level 3 [Member]	'	'
Fair value measurements	'	'
Money market funds	'	0
Recurring [Member] | Level 3 [Member] | Short-term investments [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	0
Recurring [Member] | Level 3 [Member] | Short-term investments [Member] | Certificates of deposit [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	0
Recurring [Member] | Level 3 [Member] | Short-term investments [Member] | Corporate debt securities [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	0
Recurring [Member] | Level 3 [Member] | Long-term investments [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	0
Recurring [Member] | Level 3 [Member] | Long-term investments [Member] | Corporate debt securities [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	$0

Loan_and_Security_Agreement_De

Loan and Security Agreement (Details) (USD $)	0 Months Ended	12 Months Ended
In Millions, except Share data, unless otherwise specified	Apr. 03, 2013	Dec. 31, 2012	Mar. 31, 2012	Mar. 31, 2009
Loan and Security Agreement	'	'	'	'
Notes Payable	'	'	$10	'
Number of shares of common stock exercisable under the warrants issued	'	'	'	423,971
Exercise price of warrants (in dollars per share)	'	'	'	16.78
Extinguishment of Debt, Amount	$9.80	'	'	'
Treasury note term to maturity	'	'36 months	'	'

Commitments_and_Contingencies_1

Commitments and Contingencies Commitments and Contingencies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Purchase Commitment, Excluding Long-term Commitment [Line Items]	'	'	'
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$23,000	'	'
Operating Leases, Rent Expense, Net	1,800,000	3,600,000	3,200,000
Capital Leases, Future Minimum Payments Due	$23,000	'	'

Stockholders_Equity_Details

Stockholder's Equity (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 31, 2012

Mar. 31, 2009

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2006

Mar. 31, 2012

Mar. 31, 2012

Mar. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

2011 Stock Options/Stock Issuance Plan [Member]

2006 Equity Incentive Plan [Member]

2006 Equity Incentive Plan [Member]

2006 Equity Incentive Plan [Member]

Equity Incentive, 2001 and 2006 Plans [Member]

2006 Employee Stock Purchse Plan [Member]

2006 Employee Stock Purchse Plan [Member]

2006 Employee Stock Purchse Plan [Member]

Nonqualified Stock Options [Member]

Incentive Stock Options or Nonqualified Stock Options for 10% Stockholder [Member]

Incentive Stock Options [Member]

Restricted Stock Units (RSUs) [Member]

2011 Stock Options/Stock Issuance Plan [Member]

2011 Stock Options/Stock Issuance Plan [Member]

2006 Equity Incentive Plan [Member]

2006 Equity Incentive Plan [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Designated and authorized preferred stock

10,000,000

10,000,000

10,000,000

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Par value preferred stock

$0.00

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends on preferred stock

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Par value common stock

100,000,000

100,000,000

100,000,000

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Par value common stock

$0.00

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

37,369,717

35,733,181

37,369,717

37,490,095

'

'

'

'

'

'

'

'

'

'

'

'

'

Issued lenders warrants to purchase shares of common stock

'

'

'

'

423,971

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, exercise price per share

'

'

'

'

16.78

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from common stock issued upon public offering, net of issuance costs

'

'

53,625,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from the sale of shares

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds

$0

'

$53,625,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Award vesting period

'

'

'

'

'

'4 years

'10 years

'

'

'

'

'

'

'

'

'

'3 years

Shares reserved for issuance

'

'

'

'

'

'

'

'

8,308,443

'

'

'

'

'

'

'

'

Percent ownership of stockholder

'

'

'

'

'

10.00%

10.00%

'

'

'

'

'

'

'

'

'

'

Purchase price of common stock, percent

'

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

110.00%

110.00%

'

Term over which awards become exercisable

'

'

'

'

'

'10 years

'4 years

'

'

'

'

'

'

'

'

'

'

Total number of shares of common stock outstanding, percent

'

'

'

'

'

'

'

4.50%

'

'

'

'

'

'

'

'

'

Total number of shares of common stock outstanding, shares

'

'

'

'

'

'

1,400,000

'

'

'

'

'

'

'

'

'

'

Total shares available for grant

'

'

'

'

'

'

'

'

'

4,906,238

'

'

'

'

'

'

'

Shares of common, purchased under the purchase plan

'

'

'

'

'

'

'

'

'

'

0

224,908

184,382

'

'

'

'

StockBased_Compensation_Statem

Stock-Based Compensation (Statements of Operaitons) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated Share-based Compensation Expense	$4,442,000	$11,211,000	$10,025,000
Research and Development Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated Share-based Compensation Expense	878,000	4,324,000	4,632,000
Selling, General and Administrative Expenses [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated Share-based Compensation Expense	$3,564,000	$6,887,000	$5,393,000

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock Compensation Plan [Member]	'	'	'
Stock-based compensation	'	'	'
Dividend yield	0.00%	0.00%	0.00%
Stock Options [Member]	'	'	'
Stock-based compensation	'	'	'
Granted (shares)	888,778	2,142,286	1,110,924
Weighted- average grant date fair value per share	15.79	8.26	4.41
Expected volatility	120.00%	81.00%	80.00%
Risk-free interest rate	0.77%	0.89%	1.86%
Dividend yield	0.00%	0.00%	0.00%
Expected term (in years)	'5 years 4 months 26 days	'5 years 6 months	'5 years 7 months 6 days
Restricted stock units [Member]	'	'	'
Stock-based compensation	'	'	'
Weighted- average grant date fair value per share	16.36	7.99	6.96
Granted (time-based) (shares)	393,195	184,963	220,856
Minimum [Member] | Stock Compensation Plan [Member]	'	'	'
Stock-based compensation	'	'	'
Expected volatility	50.00%	50.00%	85.00%
Risk-free interest rate	0.04%	0.04%	0.16%
Expected term (in years)	'6 months	'6 months	'6 months
Maximum [Member] | Stock Compensation Plan [Member]	'	'	'
Stock-based compensation	'	'	'
Expected volatility	106.00%	157.00%	193.00%
Risk-free interest rate	0.57%	1.00%	1.40%
Expected term (in years)	'24 months	'24 months	'24 months

StockBased_Compensation_Stock_

Stock-Based Compensation (Stock Options) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011	Mar. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'		'	'
Share-based payment award, ending balance (shares)	1,839,862		'		'	'
Options excercisable (shares)	1,551,929		'		'	'
Share-based payment award, ending balance (per share)	$16.23		'		'	'
Options exercisable (per share)	$17.06		'		'	'
Share-based payment award, ending balance, weighted average remaining contractual term	'7 years 8 months 23 days		'		'	'
Total fair value of stock options vested	$3,200,000		$6,200,000		7,200,000	'
Stock Options [Member]	'		'		'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'		'	'
Share-based payment award, beginning balance (shares)	4,857,536		'		'	'
Granted (shares)	888,778		2,142,286		1,110,924	'
Excercised (shares)	-30,918	[1]	'		'	'
Forfeited (shares)	-2,889,025		'		'	'
Cancelled (shares)	-986,514		'		'	'
Share-based payment award, ending balance (shares)	1,839,857		4,857,536		'	'
Options excercisable (shares)	1,551,929		'		'	'
Options vested (shares)	'		'		'	1,834,691
Share-based payment award, beginning balance (per share)	$13.49	[2]	'		'	'
Granted (per share)	$18.83	[2]	'		'	'
Excercised (per share)	$8.77	[1],[2]	'		'	'
Forfeited (per share)	$13.35	[2]	'		'	'
Cancelled (per share)	$13.74	[2]	'		'	'
Share-based payment award, ending balance (per share)	$16.24	[2]	$13.49	[2]	'	'
Options exercisable (per share)	$17.06	[2]	'		'	'
Options vested (per share)	'		'		'	$16.24	[2]
Share-based payment award, ending balance, weighted average remaining contractual term	'3 years 6 months 21 days		'		'	'
Options exercisable weighted average remaining contractual term	'2 years 9 months 2 days		'		'	'
Options vested weighted average remaining contractual term	'3 years 6 months 17 days		'		'	'
Options, intrinsic value	0	[3]	'		'	'
Options exercisable, Intrinsic value	0	[3]	'		'	'
Options vested, intrinsic value	$0	[3]	'		'	'
[1]	The total intrinsic value of stock options exercised was $0.3 million, $10.6 million, and $0.3 million during the years ended December 31, 2013, 2012, and 2011, respectively, and was determined at the date of each exercise.
[2]	The weighted average price per share is determined using exercise price per share for stock options and fair value per share on grant date for restricted stock units.
[3]	The aggregate intrinsic value is calculated as:•For options: the difference between the exercise price of the option and the fair value of our common stock for in-the-money options at December 31, 2013.•For restricted stock units: the difference between the grant date fair value of the unit and the fair value of our common stock for in-the-money units at December 31, 2013.

StockBased_Compensation_Restri

Stock-Based Compensation (Restricted Stock Unit Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'		'	'
Intrinsic Value of Stock Options Exercised	$300,000		$10,600,000		300,000	'
Total fair value of restricted stock units vested	100,000		800,000		900,000	'
Restricted Stock Units (RSUs) [Member]	'		'		'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'		'	'
Share-based payment award, beginning balance (shares)	296,723		'		'	'
Granted (time-based) (shares)	393,195		184,963		220,856	'
Vested (shares)	-89,460		'		'	'
Forfeited (shares)	-600,458		'		'	'
Share-based payment award, ending balance (shares)	0		296,723		'	'
Share-based payment award, beginning balance (per share)	$7.54	[1]	'		'	'
Granted (time-based) (per share)	$16.36	[1]	'		'	'
Vested (per share)	$7.58	[1]	'		'	'
Forfeited (per share)	$0	[1]	'		'	'
Share-based payment award, ending balance (per share)	$0	[1]	$7.54	[1]	'	'
Share-based payment award, ending balance, Intrinsic Value	$0	[2]	'		'	'
Board of directors approved grant	'		'		'	225,000
Milestone Payment Receivable upon Acceptance by FDA for Review of NDA [Member] | Restricted Stock Units (RSUs) [Member]	'		'		'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'		'	'
Units vested	'		'		50.00%	'
Milestone Payment Receivable Due to Progress on Commercial Launch of OMONTYS [Member] | Restricted Stock Units (RSUs) [Member]	'		'		'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'		'	'
Units vested	'		50.00%		50.00%	'
[1]	The weighted average price per share is determined using exercise price per share for stock options and fair value per share on grant date for restricted stock units.
[2]	The aggregate intrinsic value is calculated as:•For options: the difference between the exercise price of the option and the fair value of our common stock for in-the-money options at December 31, 2013.•For restricted stock units: the difference between the grant date fair value of the unit and the fair value of our common stock for in-the-money units at December 31, 2013.

StockBased_Compensation_Stock_1

Stock-Based Compensation (Stock Options Outstanding and Exercisable) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of shares	1,839,862
Weighted- average remaining contractual life in years	'7 years 8 months 23 days
Weighted- average exercise price per share	$16.23
Number of shares	1,551,929
Weighted- average exercise price per share	$17.06
$0.80 - $10.06 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise prices, lower range limit	$0.80
Range of exercise prices, upper range limit	$10.06
Number of shares	728,358
Weighted- average remaining contractual life in years	'8 years 2 months 16 days
Weighted- average exercise price per share	$7.31
Number of shares	542,799
Weighted- average exercise price per share	$7.32
$10.06 - $20.22 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise prices, lower range limit	$10.06
Range of exercise prices, upper range limit	$20.22
Number of shares	417,558
Weighted- average remaining contractual life in years	'8 years 1 month 13 days
Weighted- average exercise price per share	$16.87
Number of shares	333,921
Weighted- average exercise price per share	$16.23
$20.22 - $30.27 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise prices, lower range limit	$20.22
Range of exercise prices, upper range limit	$30.27
Number of shares	583,246
Weighted- average remaining contractual life in years	'6 years 9 months 22 days
Weighted- average exercise price per share	$23.56
Number of shares	564,509
Weighted- average exercise price per share	$23.59
$30.27 - $36.43 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise prices, lower range limit	$30.27
Range of exercise prices, upper range limit	$36.43
Number of shares	110,700
Weighted- average remaining contractual life in years	'3 years 9 months 11 days
Weighted- average exercise price per share	$33.97
Number of shares	110,700
Weighted- average exercise price per share	$33.97
$0.80 - 36.43 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise prices, lower range limit	$0.80
Range of exercise prices, upper range limit	$36.43

StockBased_Compensation_Detail1

Stock-Based Compensation (Details Textual) (USD $)

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2003

Sep. 30, 2003

Stock Compensation Plan [Member]

Stock Compensation Plan [Member]

Stock Compensation Plan [Member]

Stock Options [Member]

Stock Options [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Nonemployee Stock Option [Member]

Nonemployee Stock Option [Member]

Nonemployee Stock Option [Member]

Upper Limit of Existing Employee Deemed to be Fair Market Value [Member]

Lower Limit of Existing Employee Stock Option, Deemed to be Fair Market Value [Member]

Share-based Compensation [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized

$2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition

'

'1 year 9 months 24 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total fair value of restricted stock units vested

100,000

800,000

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average fair value of stock purchase right

'

'

'

$0

$4.36

$2.63

'

'

'

'

'

'

'

'

'

'

Purcchase plan eligibility

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

4,442,000

11,211,000

10,025,000

'

'

'

'

'

-3,000

87,000

-5,000

'

'

'

'

'

Approved repricing of stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4

$0.80

Number of shares

1,839,862

'

'

'

'

'

1,839,857

4,857,536

'

'

'

'

'

'

'

'

Deferred stock-based compensation (benefit) related to stock options

'

'

'

'

'

'

'

'

-3,000

87,000

-5,000

'

'

'

'

'

Nonemployee stock-based compensation (benefit) expense

'

'

'

'

'

'

'

'

'

'

'

$1,000

$69,000

($10,000)

'

'

Restructuring_Charge_Details

Restructuring Charge (Details) (USD $)

1 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

Mar. 31, 2012

Dec. 31, 2013

31-May-10

Dec. 31, 2011

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

sqft

sqft

Facilities Related [Member]

New Sublease Agreement [Member]

2011 restructuring [Member]

2011 restructuring [Member]

2011 restructuring [Member]

2011 restructuring [Member]

2011 restructuring [Member]

2011 restructuring [Member]

2011 restructuring [Member]

2011 restructuring [Member]

2011 restructuring [Member]

2013 restructuring [Member]

2013 restructuring [Member]

2013 restructuring [Member]

Facilities Related [Member]

Facilities Related [Member]

Facilities Related [Member]

Employee Related [Member]

Employee Related [Member]

Employee Related [Member]

Facilities Related [Member]

Employee Related [Member]

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring Charges

'

$16,066,000

'

$869,000

'

'

$83,000

$1,844,000

'

$77,000

$869,000

'

$6,000

$975,000

$17,266,000

$2,500,000

$14,766,000

Accretion Expense

'

'

'

72,000

'

'

11,000

72,000

'

11,000

72,000

'

0

0

'

'

'

Area of real estate property subleased (in square feet)

'

8,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Area of additional office space possessed as a result of May 2010 amendment to operating lease (in square feet)

'

16,000

16,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of sublease

'28 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring Reserve, Settled with Cash

'

'

'

'

'

'

-423,000

-1,141,000

'

-214,000

-431,000

'

-209,000

-710,000

15,751,000

2,500,000

13,251,000

Accrual balance and utilization by type for the restructuring

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at the beginning of the period

'

'

'

'

'

-29,000

775,000

0

-29,000

510,000

0

0

265,000

0

0

0

0

Balance at the end of the period

'

'

'

'

'

0

-29,000

775,000

0

-29,000

510,000

0

0

265,000

315,000

0

315,000

Adjustments

'

'

'

'

($336,000)

$29,000

'

'

$29,000

'

'

$0

'

'

($1,200,000)

$0

($1,200,000)

Income_Taxes_Provision_for_Inc

Income Taxes (Provision for Income Taxes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current provision (benefit) for income taxes:	'	'	'
Federal	($26)	($27)	$0
State	-2,132	1	1
Total current provision (benefit) for income taxes	-2,158	-26	1
Deferred tax benefit:	'	'	'
Federal	0	0	0
State	0	0	0
Total deferred tax benefit	0	0	0
Provision (benefit) for income taxes	($2,158)	($26)	$1

Income_Taxes_Reconciliation_of

Income Taxes (Reconciliation of Federal Statutory Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Federal statutory income tax rate	-35.00%	-35.00%	-35.00%
State income taxes, net of federal benefit	-12.85%	0.00%	0.00%
Stock-based compensation expense	9.76%	3.04%	4.15%
Change in valuation allowance	-7.89%	32.52%	-56.26%
Change in federal rates and prior year true ups	32.81%	-0.64%	0.70%
Permanent differences	0.32%	0.08%	0.08%
Tax credits	0.00%	0.00%	2.66%
Changes in tax reserves	-0.15%	-0.03%	0.00%
Impairment of tax attributes due to ownership change	0.00%	0.00%	83.67%
Provision (benefit) for income taxes	-13.00%	-0.03%	0.00%

Income_Taxes_Deferred_Tax_Asse

Income Taxes (Deferred Tax Assets) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
Net operating loss carryforwards	$138,165	$113,956
Federal and State credit carryforwards	4,263	4,249
Depreciation and amortization	8,174	11,866
Capitalized start-up costs	1,037	1,185
Accrued liabilities and allowances	6,694	35,955
Gross deferred tax assets	158,333	167,211
Deferred tax liability	0	0
Net deferred tax asset	158,333	167,211
Less: Valuation allowance	-158,333	-159,971
Net deferred tax assets	$0	$7,240

Income_Taxes_Reconciliation_of1

Income Taxes (Reconciliation of Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Tax Disclosure [Abstract]	'	'	'	'
Balance at beginning of year	$70,854	$73,017	$70,613	$13,100
Additions for current year tax positions	0	0	59,419	'
Additions for prior year tax positions	0	2,437	0	'
Reductions for statute of limitations	-1,825	-27	0	'
Reductions for prior year tax positions	-338	-6	-1,906	'
Balance at end of year	$70,854	$73,017	$70,613	$13,100

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Other Tax Carryforward [Line Items]	'	'	'	'
Increase (decrease) in valuation allowance	$1,600,000	($35,400,000)	'	'
Reduction of gross deferred tax asset expiring carryforwards	'	'	59,600,000	'
Net deferred tax assets	0	7,240,000	'	'
Liability for uncertain income tax positions	0	10,062,000	'	'
Interest expense related to uncertain income tax positions	-667,000	-322,000	144,000	'
Accrued interest expense related to liability for uncertain income tax positions	0	664,000	'	'
Unrecognized tax benefits	70,854,000	73,017,000	70,613,000	13,100,000
Unrecognized tax benefits that would impact effective tax rate	70,900,000	65,800,000	'	'
Equity [Member]	'	'	'	'
Other Tax Carryforward [Line Items]	'	'	'	'
Increase (decrease) in valuation allowance	5,100,000	'	'	'
Federal [Member]	'	'	'	'
Other Tax Carryforward [Line Items]	'	'	'	'
Operating loss carryforwards	481,000,000	'	'	'
Tax credit carryforwards	9,000,000	'	'	'
State [Member]	'	'	'	'
Other Tax Carryforward [Line Items]	'	'	'	'
Operating loss carryforwards	491,000,000	'	'	'
Tax credit carryforwards	$7,000,000	'	'	'

Retirement_Savings_Plan_Detail

Retirement Savings Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]	'	'	'
Employer discretionary contribution amount	$0	$895,000	$407,000

Quarterly_Financial_Data_Detai

Quarterly Financial Data (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Collaboration revenue	$0	$0	$525	$839	$14,796	$13,603	$2,754	$63,205	$1,364	$94,358	$47,703
Total revenue	0	0	525	844	14,799	13,607	2,755	63,209	1,369	94,370	47,720
Income (loss) from operations	-1,058	-1,692	14,271	-26,196	-68,188	-23,990	-31,381	31,520	-15,046	-92,039	-61,406
Net income (loss)	($1,059)	($1,692)	$15,372	($26,674)	($68,271)	($24,638)	($31,956)	$31,453	'	'	'
Basic net income (loss) per common share	($0.03)	($0.05)	$0.41	($0.71)	($1.85)	($0.68)	($0.89)	$0.88	'	'	'
Weighted-average number of common shares used in computing basic net income (loss) per common share calculation	37,490	37,490	37,490	37,469	'	'	'	'	'	'	'
Diluted net income (loss) per common share	($0.03)	($0.05)	$0.41	($0.71)	($1.85)	($0.68)	($0.89)	$0.87	'	'	'
Weighted-average number of common shares used in computing diluted net income (loss) per common share calculation	37,490	37,490	37,495	37,469	36,846	36,350	36,075	36,338	'	'	'
Weighted-average number of common shares used in computing basic net income (loss) per common share calculation	'	'	'	'	36,846	36,350	36,075	35,772	37,448	36,342	33,288

Quarterly_Financial_Data_Detai1

Quarterly Financial Data (Details Textual) (USD $)	Dec. 31, 2013		Mar. 31, 2013	Dec. 31, 2012		Sep. 30, 2013	Dec. 31, 2012
						Commercial API Supply Agreement [Member]	Commercial API Supply Agreement [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]	'		'	'		'	'
Inventory write-down	'		'	'		$10,400,000	'
Accrued Losses Purchase Commitments	$0	[1]	$32,900,000	$34,599,000	[1]	'	$10,400,000
[1]	{F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjY1NGY0YjEwZDNhNTQ0NzJhYzQ2NmIxODFkYjEyZWYwfFRleHRTZWxlY3Rpb246ODc2MzJCQ0FBQUE2M0ZFNDM4OTlCNDZDNDYzNTFCQ0QM}